<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0140673621023473</prism:url><dc:identifier>doi:10.1016/S0140-6736(21)02347-3</dc:identifier><eid>1-s2.0-S0140673621023473</eid><prism:doi>10.1016/S0140-6736(21)02347-3</prism:doi><pii>S0140-6736(21)02347-3</pii><dc:title>NCD Countdown 2030: efficient pathways and strategic investments to accelerate progress towards the Sustainable Development Goal target 3.4 in low-income and middle-income countries </dc:title><prism:publicationName>The Lancet</prism:publicationName><prism:aggregationType>Journal</prism:aggregationType><pubType>rev</pubType><prism:issn>01406736</prism:issn><prism:volume>399</prism:volume><prism:issueIdentifier>10331</prism:issueIdentifier><prism:startingPage>1266</prism:startingPage><prism:endingPage>1278</prism:endingPage><prism:pageRange>1266-1278</prism:pageRange><prism:number>10331</prism:number><dc:format>text/xml</dc:format><prism:coverDate>2022-04-01</prism:coverDate><prism:coverDisplayDate>26 March–1 April 2022</prism:coverDisplayDate><prism:copyright>© 2021 Elsevier Ltd. All rights reserved.</prism:copyright><prism:publisher>Elsevier Ltd.</prism:publisher><dc:creator>Watkins, David A</dc:creator><dc:creator>Msemburi, William T</dc:creator><dc:creator>Pickersgill, Sarah J</dc:creator><dc:creator>Kawakatsu, Yoshito</dc:creator><dc:creator>Gheorghe, Adrian</dc:creator><dc:creator>Dain, Katie</dc:creator><dc:creator>Johansson, Kjell Arne</dc:creator><dc:creator>Said, Sanaa</dc:creator><dc:creator>Renshaw, Nina</dc:creator><dc:creator>Tolla, Mieraf T</dc:creator><dc:creator>Twea, Pakwanja D</dc:creator><dc:creator>Varghese, Cherian</dc:creator><dc:creator>Chalkidou, Kalipso</dc:creator><dc:creator>Ezzati, Majid</dc:creator><dc:creator>Norheim, Ole Frithjof</dc:creator><dc:description>
                  Most countries have made little progress in achieving the Sustainable Development Goal (SDG) target 3.4, which calls for a reduction in premature mortality from non-communicable diseases (NCDs) by a third from 2015 to 2030. In this Health Policy paper, we synthesise the evidence related to interventions that can reduce premature mortality from the major NCDs over the next decade and that are feasible to implement in countries at all levels of income. Our recommendations are intended as generic guidance to help 123 low-income and middle-income countries meet SDG target 3.4; country-level applications require additional analyses and consideration of the local implementation and utilisation context. Protecting current investments and scaling up these interventions is especially crucial in the context of COVID-19-related health system disruptions. We show how cost-effectiveness data and other information can be used to define locally tailored packages of interventions to accelerate rates of decline in NCD mortality. Under realistic implementation constraints, most countries could achieve (or almost achieve) the NCD target using a combination of these interventions; the greatest gains would be for cardiovascular disease mortality. Implementing the most efficient package of interventions in each world region would require, on average, an additional US$18 billion annually over 2023–30; this investment could avert 39 million deaths and generate an average net economic benefit of $2·7 trillion, or $390 per capita. Although specific clinical intervention pathways would vary across countries and regions, policies to reduce behavioural risks, such as tobacco smoking, harmful use of alcohol, and excess sodium intake, would be relevant in nearly every country, accounting for nearly two-thirds of the health gains of any locally tailored NCD package. By 2030, ministries of health would need to contribute about 20% of their budgets to high-priority NCD interventions. Our report concludes with a discussion of financing and health system implementation considerations and reflections on the NCD agenda beyond the SDG target 3.4 and beyond the SDG period.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessArticle><openaccessType/><openArchiveArticle>false</openArchiveArticle><openaccessSponsorName/><openaccessSponsorType/><openaccessUserLicense/><link href="https://api.elsevier.com/content/article/pii/S0140673621023473" rel="self"/><link href="https://www.sciencedirect.com/science/article/pii/S0140673621023473" rel="scidir"/></coredata><objects><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="938" height="476" size="127496">https://api.elsevier.com/content/object/eid/1-s2.0-S0140673621023473-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="938" height="719" size="127771">https://api.elsevier.com/content/object/eid/1-s2.0-S0140673621023473-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="111" size="9338">https://api.elsevier.com/content/object/eid/1-s2.0-S0140673621023473-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="214" height="164" size="8039">https://api.elsevier.com/content/object/eid/1-s2.0-S0140673621023473-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="4152" height="2107" size="1033465">https://api.elsevier.com/content/object/eid/1-s2.0-S0140673621023473-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="4152" height="3184" size="983372">https://api.elsevier.com/content/object/eid/1-s2.0-S0140673621023473-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="3163944">https://api.elsevier.com/content/object/eid/1-s2.0-S0140673621023473-mmc1.pdf?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="580979">https://api.elsevier.com/content/object/eid/1-s2.0-S0140673621023473-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85126987270</scopus-id><scopus-eid>2-s2.0-85126987270</scopus-eid><pubmed-id>35339227</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85126987270" rel="abstract"/><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271074</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291682</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>The Lancet</xocs:srctitle>
      <xocs:normalized-srctitle>LANCET</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20220324">2022-03-24</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20220324">2022-03-24</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20220324">2022-03-24</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20220324">2022-03-24</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2022-07-15T20:54:10</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0140673621023473</xocs:eid>
      <xocs:pii-formatted>S0140-6736(21)02347-3</xocs:pii-formatted>
      <xocs:pii-unformatted>S0140673621023473</xocs:pii-unformatted>
      <xocs:doi>10.1016/S0140-6736(21)02347-3</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.3</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0140673622X00123</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20230206">2023-02-06T23:59:30.210405Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20220326</xocs:date-search-begin>
      <xocs:date-search-end>20220401</xocs:date-search-end>
      <xocs:year-nav>2022</xocs:year-nav>
      <xocs:indexeddate epoch="1648167942">2022-03-25T00:25:42.901302Z</xocs:indexeddate>
      <xocs:articleinfo>articleinfo articletitlenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issfirst issn issnnorm issuelist itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdateend pubdatestart pubdatetxt pubyr sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge appendices articletitle auth authfull doctopic footnotes primabst pubtype ref</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0140-6736</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>01406736</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>399</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>399</xocs:volume>
      </xocs:volume-list>
      <xocs:iss-first>10331</xocs:iss-first>
      <xocs:issue-list>
         <xocs:issue>10331</xocs:issue>
      </xocs:issue-list>
      <xocs:vol-iss-suppl-text>Volume 399, Issue 10331</xocs:vol-iss-suppl-text>
      <xocs:sort-order>28</xocs:sort-order>
      <xocs:first-fp>1266</xocs:first-fp>
      <xocs:last-lp>1278</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>1266</xocs:first-page>
         <xocs:last-page>1278</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20220326</xocs:start-date>
         <xocs:end-date>20220401</xocs:end-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>26 March–1 April 2022</xocs:cover-date-text>
      <xocs:cover-date-start>2022-03-26</xocs:cover-date-start>
      <xocs:cover-date-end>2022-04-01</xocs:cover-date-end>
      <xocs:cover-date-year>2022</xocs:cover-date-year>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>rev</xocs:document-subtype>
      <xocs:copyright-line>© 2021 Elsevier Ltd. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>NCDCOUNTDOWN2030EFFICIENTPATHWAYSSTRATEGICINVESTMENTSACCELERATEPROGRESSTOWARDSSUSTAINABLEDEVELOPMENTGOALTARGET34INLOWINCOMEMIDDLEINCOMECOUNTRIES</xocs:normalized-article-title>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Identifying candidate interventions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Prospects for reducing mortality from specific NCDs</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Cost-effectiveness considerations</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Efficient pathways to achieving SDG target 3.4</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Costs and benefits of achieving SDG target 3.4</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Domestic financing to achieve SDG target 3.4</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>The role of development partners and international finance</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Non-financial implementation considerations</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Limitations and caveats</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Conclusion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>NCD Countdown 2030 collaborators</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-section-title>Supplementary Material</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sbref10"/>
         <xocs:ref-info refid="sbref20">
            <xocs:ref-normalized-surname>EZZATI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>508</xocs:ref-first-fp>
            <xocs:ref-last-lp>530</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref30">
            <xocs:ref-normalized-surname>EZZATI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1482</xocs:ref-first-fp>
            <xocs:ref-last-lp>1487</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref40">
            <xocs:ref-normalized-surname>WATKINS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1434</xocs:ref-first-fp>
            <xocs:ref-last-lp>1460</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref50">
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1072</xocs:ref-first-fp>
            <xocs:ref-last-lp>1088</xocs:ref-last-lp>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref60">
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>918</xocs:ref-first-fp>
            <xocs:ref-last-lp>934</xocs:ref-last-lp>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref70">
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>RAPIDASSESSMENTSERVICEDELIVERYFORNCDSDURINGCOVID19PANDEMIC</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref80">
            <xocs:ref-normalized-surname>HARRISON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>330</xocs:ref-first-fp>
            <xocs:ref-last-lp>339</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref90">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>298</xocs:ref-first-fp>
            <xocs:ref-last-lp>307</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref100">
            <xocs:ref-normalized-surname>GERAYELI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-article-number>100789</xocs:ref-article-number>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref110">
            <xocs:ref-normalized-surname>KONTIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2022</xocs:ref-pub-year>
            <xocs:ref-first-fp>279</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref120">
            <xocs:ref-pub-year>1993</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>WORLDDEVELOPMENTREPORT1993INVESTINGINHEALTH</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref130">
            <xocs:ref-normalized-surname>LAXMINARAYAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>1193</xocs:ref-first-fp>
            <xocs:ref-last-lp>1208</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref140">
            <xocs:ref-normalized-surname>JAMISON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1108</xocs:ref-first-fp>
            <xocs:ref-last-lp>1120</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref150">
            <xocs:ref-normalized-surname>GELBAND</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>2133</xocs:ref-first-fp>
            <xocs:ref-last-lp>2144</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref160">
            <xocs:ref-normalized-surname>PRABHAKARAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1224</xocs:ref-first-fp>
            <xocs:ref-last-lp>1236</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref170"/>
         <xocs:ref-info refid="sbref180">
            <xocs:ref-normalized-surname>BUKHMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>991</xocs:ref-first-fp>
            <xocs:ref-last-lp>1044</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref190">
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>GLOBALHEALTHESTIMATESLIFEEXPECTANCYLEADINGCAUSESDEATHDISABILITY</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref200">
            <xocs:ref-normalized-surname>KONTIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>427</xocs:ref-first-fp>
            <xocs:ref-last-lp>437</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref210">
            <xocs:ref-normalized-surname>WATKINS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-article-number>e001335</xocs:ref-article-number>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref220">
            <xocs:ref-normalized-surname>WATKINS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>e829</xocs:ref-first-fp>
            <xocs:ref-last-lp>e839</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref230">
            <xocs:ref-normalized-surname>CHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>167</xocs:ref-first-fp>
            <xocs:ref-last-lp>181</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>DISEASECONTROLPRIORITIESIMPROVINGHEALTHREDUCINGPOVERTY</xocs:ref-normalized-srctitle>
            <xocs:ref-normalized-article-title>BENEFITCOSTANALYSISINDISEASECONTROLPRIORITIES</xocs:ref-normalized-article-title>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref240">
            <xocs:ref-normalized-surname>JAMISON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1898</xocs:ref-first-fp>
            <xocs:ref-last-lp>1955</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref250">
            <xocs:ref-normalized-surname>OCHALEK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>COSTPERDALYAVERTEDTHRESHOLDSFORLOWMIDDLEINCOMECOUNTRIESEVIDENCECROSSCOUNTRYDATA</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref260">
            <xocs:ref-normalized-surname>CHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>2019</xocs:ref-first-fp>
            <xocs:ref-last-lp>2082</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref270">
            <xocs:ref-normalized-surname>ROBINSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>REFERENCECASEGUIDELINESFORBENEFITCOSTANALYSISINGLOBALHEALTHDEVELOPMENT</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref280">
            <xocs:ref-normalized-surname>STENBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>e875</xocs:ref-first-fp>
            <xocs:ref-last-lp>e887</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref290">
            <xocs:ref-normalized-surname>WATKINS</xocs:ref-normalized-surname>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref300">
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>HEALTHSECTORRESOURCEMAPPINGFY201718FY201920</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref310">
            <xocs:ref-normalized-surname>SANKOH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>e33</xocs:ref-first-fp>
            <xocs:ref-last-lp>e34</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref320">
            <xocs:ref-normalized-surname>BARROY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>214</xocs:ref-first-fp>
            <xocs:ref-last-lp>226</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref330">
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>FINALREPORTRECOMMENDATIONSWORKINGGROUPWAYSMEANSENCOURAGINGMEMBERSTATESNONSTATEACTORSREALIZECOMMITMENTINCLUDEDINPARAGRAPH45DPOLITICALDECLARATIONHIGHLEVELMEETINGUNGENERALASSEMBLYPREVENTIONCONTROLNONCOMMUNICABLEDISEASES</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref340">
            <xocs:ref-normalized-surname>OROXOM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>STRUCTURINGFUNDINGDEVELOPMENTIMPACTBONDSFORHEALTHNINELESSONSCAMEROONBEYOND</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref350">
            <xocs:ref-normalized-surname>COADY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>11</xocs:ref-first-fp>
            <xocs:ref-last-lp>27</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref360">
            <xocs:ref-normalized-surname>VERGUET</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>e288</xocs:ref-first-fp>
            <xocs:ref-last-lp>e296</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref370">
            <xocs:ref-normalized-surname>JAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>2047</xocs:ref-first-fp>
            <xocs:ref-last-lp>2058</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref380">
            <xocs:ref-normalized-surname>VANBIESEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>e63</xocs:ref-first-fp>
            <xocs:ref-last-lp>e71</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref390">
            <xocs:ref-normalized-surname>RUIZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1313</xocs:ref-first-fp>
            <xocs:ref-last-lp>1323</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref400">
            <xocs:ref-normalized-surname>ISARANUWATCHAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>m141</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref410">
            <xocs:ref-normalized-surname>EREGATA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-article-number>e1829313</xocs:ref-article-number>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref420">
            <xocs:ref-normalized-surname>ROTH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1736</xocs:ref-first-fp>
            <xocs:ref-last-lp>1788</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref430">
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>ETHIOPIASTEPSREPORTRISKFACTORSFORNONCOMMUNICABLEDISEASESPREVALENCESELECTEDNCDS</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref440">
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>ETHIOPIASERVICESAVAILABILITYREADINESSASSESSMENT</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref450">
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>ETHIOPIAHEALTHACCOUNTS201617</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref460">
            <xocs:ref-normalized-surname>TOLLA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-article-number>e000280</xocs:ref-article-number>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref470">
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>ESSENTIALHEALTHSERVICESPACKAGEETHIOPIA</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref480">
            <xocs:ref-normalized-surname>JAILOBAEVA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>68</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref490"/>
         <xocs:ref-info refid="sbref500">
            <xocs:ref-normalized-surname>COLLINS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-article-number>l4499</xocs:ref-article-number>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref510">
            <xocs:ref-normalized-surname>NUGENT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>S83</xocs:ref-first-fp>
            <xocs:ref-last-lp>S92</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref520">
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>BETTERHEALTHBETTERLIVESCOMBATINGNONCOMMUNICABLEDISEASESINCONTEXTNORWEGIANDEVELOPMENTPOLICY202024</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref530">
            <xocs:ref-normalized-surname>KLUGE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>1678</xocs:ref-first-fp>
            <xocs:ref-last-lp>1680</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref540">
            <xocs:ref-normalized-surname>KOSTOVA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>288</xocs:ref-first-fp>
            <xocs:ref-last-lp>301</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref550">
            <xocs:ref-normalized-surname>BERTRAM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-article-number>l1648</xocs:ref-article-number>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref560">
            <xocs:ref-normalized-surname>BERTRAM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>2071</xocs:ref-first-fp>
            <xocs:ref-last-lp>2078</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref570">
            <xocs:ref-normalized-surname>HORTON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-article-number>e0182951</xocs:ref-article-number>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref580">
            <xocs:ref-normalized-surname>FOREMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>2052</xocs:ref-first-fp>
            <xocs:ref-last-lp>2090</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref590">
            <xocs:ref-normalized-surname>ALLEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>e50</xocs:ref-first-fp>
            <xocs:ref-last-lp>e58</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref600">
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>INTERSECTORALACTIONHEALTHAPATHFORPOLICYMAKERSIMPLEMENTEFFECTIVESUSTAINABLEINTERSECTORALACTIONHEALTH</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref610">
            <xocs:ref-normalized-surname>DELOBELLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>727</xocs:ref-first-fp>
            <xocs:ref-last-lp>731</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref620">
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>REPORTGLOBALTOBACCOEPIDEMIC2017MONITORINGTOBACCOUSEPREVENTIONPOLICIES</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref630">
            <xocs:ref-normalized-surname>LANE</xocs:ref-normalized-surname>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref640">
            <xocs:ref-normalized-surname>CURTI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>s53</xocs:ref-first-fp>
            <xocs:ref-last-lp>s60</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref650">
            <xocs:ref-normalized-surname>WATKINS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>442</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref660">
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>957</xocs:ref-first-fp>
            <xocs:ref-last-lp>980</xocs:ref-last-lp>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref670">
            <xocs:ref-normalized-surname>KEMP</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>S93</xocs:ref-first-fp>
            <xocs:ref-last-lp>105</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref680">
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>AGUIDEIMPLEMENTATIONRESEARCHINPREVENTIONCONTROLNONCOMMUNICABLEDISEASES</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref690">
            <xocs:ref-normalized-surname>HOFFERHAWLIK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>63</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref700">
            <xocs:ref-normalized-surname>GOSPODAROWICZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>195</xocs:ref-first-fp>
            <xocs:ref-last-lp>210</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>CANCERDISEASECONTROLPRIORITIES</xocs:ref-normalized-srctitle>
            <xocs:ref-normalized-article-title>CANCERSERVICESCOMPREHENSIVECANCERCENTER</xocs:ref-normalized-article-title>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref710">
            <xocs:ref-normalized-surname>HENSHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>1229</xocs:ref-first-fp>
            <xocs:ref-last-lp>1243</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>DISEASECONTROLPRIORITIESINDEVELOPINGCOUNTRIES</xocs:ref-normalized-srctitle>
            <xocs:ref-normalized-article-title>REFERRALHOSPITALS</xocs:ref-normalized-article-title>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref720">
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>MAKINGFAIRCHOICESPATHUNIVERSALHEALTHCOVERAGEFINALREPORTCONSULTATIVEGROUPEQUITYUNIVERSALHEALTHCOVERAGE</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref730">
            <xocs:ref-normalized-surname>EBRAHIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>438</xocs:ref-first-fp>
            <xocs:ref-last-lp>440</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref740">
            <xocs:ref-normalized-surname>NUGENT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>2029</xocs:ref-first-fp>
            <xocs:ref-last-lp>2035</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys/>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2022-09-24T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2022-09-24T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2021 Elsevier Ltd. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2022-03-28T23:13:59.625Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined</xocs:funding-addon-type>
      </xocs:funding-list>
      <xocs:third-party>
         <xocs:third-party-status>0</xocs:third-party-status>
      </xocs:third-party>
      <xocs:article-sharing-framework>
         <xocs:asf-license>https://doi.org/10.15223/policy-017</xocs:asf-license>
         <xocs:asf-license>https://doi.org/10.15223/policy-037</xocs:asf-license>
         <xocs:asf-license>https://doi.org/10.15223/policy-012</xocs:asf-license>
         <xocs:asf-license>https://doi.org/10.15223/policy-029</xocs:asf-license>
         <xocs:asf-license>https://doi.org/10.15223/policy-004</xocs:asf-license>
      </xocs:article-sharing-framework>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0140-6736(21)02347-3</xocs:pii-formatted>
         <xocs:pii-unformatted>S0140673621023473</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0140673621023473</xocs:eid>
         <xocs:doi>10.1016/S0140-6736(21)02347-3</xocs:doi>
         <xocs:cid>271074</xocs:cid>
         <xocs:timestamp>2023-02-06T23:59:30.210405Z</xocs:timestamp>
         <xocs:cover-date-start>2022-03-26</xocs:cover-date-start>
         <xocs:cover-date-end>2022-04-01</xocs:cover-date-end>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0140673621023473-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0140673621023473/MAIN/application/pdf/4e70e6d150f6c0b44445330c96bef3a4/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>1191044</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>13</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0140673621023473-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0140673621023473/PREVIEW/image/png/8c6485e84f38db620f4792aabe08e7e0/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>93416</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0140673621023473-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0140673621023473/gr1/DOWNSAMPLED/image/jpeg/ee05e41200560b44042516e4b7f581a4/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>127496</xocs:filesize>
               <xocs:pixel-height>476</xocs:pixel-height>
               <xocs:pixel-width>938</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0140673621023473-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0140673621023473/gr2/DOWNSAMPLED/image/jpeg/b76c6105b43a64daaf7e016b633a46c0/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>127771</xocs:filesize>
               <xocs:pixel-height>719</xocs:pixel-height>
               <xocs:pixel-width>938</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0140673621023473-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0140673621023473/gr1/THUMBNAIL/image/gif/bd3b1a8e9536b0d609df1e064595ddc0/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9338</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0140673621023473-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0140673621023473/gr2/THUMBNAIL/image/gif/8a61bca1945f5abef2bf445e0756dd13/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8039</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>214</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0140673621023473-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0140673621023473/HIGHRES/image/jpeg/831b80cba2b3ccae34de73a18cfd2e77/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1033465</xocs:filesize>
               <xocs:pixel-height>2107</xocs:pixel-height>
               <xocs:pixel-width>4152</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0140673621023473-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0140673621023473/HIGHRES/image/jpeg/af940cc148bdb996ceb8cab9259a2248/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>983372</xocs:filesize>
               <xocs:pixel-height>3184</xocs:pixel-height>
               <xocs:pixel-width>4152</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0140673621023473-mmc1.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0140673621023473/mmc1/MAIN/application/pdf/938ffd2d273d89873775f9c60da3791d/mmc1.pdf</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>false</xocs:pdf-optimized>
               <xocs:filesize>3163944</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0140673621023473-am.pdf</xocs:attachment-eid>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:filesize>580979</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10H1BMSN73X/MAIN/application/pdf/da58d73d337e4a6c744df69007320c2f/am.pdf</xocs:ucs-locator>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="rev" version="5.6" xml:lang="en">
         <item-info>
            <jid>LANCET</jid>
            <aid>11169</aid>
            <ce:pii>S0140-6736(21)02347-3</ce:pii>
            <ce:doi>10.1016/S0140-6736(21)02347-3</ce:doi>
            <ce:copyright type="full-transfer" year="2022">Elsevier Ltd</ce:copyright>
            <ce:doctopics>
               <ce:doctopic id="cedoct10">
                  <ce:text>Review and Opinion</ce:text>
               </ce:doctopic>
               <ce:doctopic id="cedoct20">
                  <ce:text>Health Policy</ce:text>
               </ce:doctopic>
            </ce:doctopics>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Figure 1</ce:label>
               <ce:caption id="cecap10">
                  <ce:simple-para id="spara10" role="caption" view="all">Achievable reductions in cause-specific mortality from scale-up of priority NCD interventions across low-income and middle-income countries</ce:simple-para>
                  <ce:simple-para id="spara20" role="key" view="all">The density plots show the distribution of the rate of change in cause-specific mortality across all 123 low-income and middle-income countries. We compare historical (2015–19) average annual rates of change to average annual rates of change that would be observed over the period of 2015–30 if all interventions in <ce:cross-ref id="cecref10" refid="tbl1">table 1</ce:cross-ref> were simultaneously fully implemented in 2023 (including all clinical interventions at 90% population coverage). The vertical dotted line marks the annual rate of change of –2·67%, which corresponds to a reduction in cause-specific mortality by a third over 15 years. The final row shows the distribution of the rate of change in the probability of death from NCD4 between ages 30 and 70 years (ie, the metric for the Sustainable Development Goal target 3.4) as a whole. NCDs=non-communicable diseases. NCD4=four main non-communicable diseases (cancer, cardiovascular diseases, chronic respiratory diseases, and diabetes).</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0140673621023473/gr1"/>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Figure 2</ce:label>
               <ce:caption id="cecap20">
                  <ce:simple-para id="spara30" role="caption" view="all">Cost-effectiveness of priority clinical interventions for NCDs, by world region</ce:simple-para>
                  <ce:simple-para id="spara40" role="key" view="all">The values reflect the ranking of each intervention from largest to smallest change in the probability of death from NCD4 between ages 30 and 70 years resulting from a US$1 million increase in spending over 2023–30 in each region (for a list of countries in each region see <ce:cross-ref id="cecref20" refid="sec1">appendix p 36</ce:cross-ref>). Cost-effectiveness (<ce:cross-ref id="cecref30" refid="sec1">appendix pp 7–9</ce:cross-ref>) is evaluated from the perspective of the health-care system. To allow comparison with other studies, the values are also colour-coded on the basis of their cost-effectiveness in US dollars per disability-adjusted life-year averted as a share of gross domestic product per capita. Cardiovascular diseases include ischaemic heart disease and ischaemic and haemorrhagic stroke. Costs are in 2020 US dollars. NCDs=non-communicable diseases. NCD4=four main non-communicable diseases (cancer, cardiovascular diseases, chronic respiratory diseases, and diabetes). COPD=chronic obstructive pulmonary disease.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0140673621023473/gr2"/>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl1" frame="topbot" rowsep="0" colsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cecap30">
                  <ce:simple-para id="spara50" role="caption" view="all">High-priority intervention options for reducing mortality from non-communicable diseases</ce:simple-para>
               </ce:caption>
               <tgroup cols="2">
                  <colspec colnum="1" colname="col1"/>
                  <colspec colnum="2" colname="col2"/>
                  <thead>
                     <row valign="top" rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Countdown cause groups</bold>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" namest="col1" nameend="col2">
                           <bold>Intersectoral policies</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Alcohol excise taxes</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">All</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Alcohol regulations</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">All</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Tobacco excise taxes</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">All</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Smoking regulations and information, education, and communication</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">All</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Sodium reduction measures</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ischaemic heart disease, ischaemic stroke, haemorrhagic stroke, all other cardiovascular diseases</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Trans fat bans</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ischaemic heart disease</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" namest="col1" nameend="col2">
                           <bold>Community platform</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pulmonary rehabilitation</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Chronic respiratory diseases</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" namest="col1" nameend="col2">
                           <bold>Health centre platform</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Primary prevention for cardiovascular disease</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ischaemic heart disease, ischaemic stroke, haemorrhagic stroke, all other cardiovascular diseases</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Secondary prevention for cardiovascular disease</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ischaemic heart disease, ischaemic stroke, all other cardiovascular diseases</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Aspirin for suspected acute coronary syndrome</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ischaemic heart disease</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Chronic treatment for heart failure</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ischaemic heart disease, all other cardiovascular diseases</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Chronic treatment for asthma and COPD</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Chronic respiratory diseases</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Diabetes screening and treatment</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Diabetes</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" namest="col1" nameend="col2">
                           <bold>First-level hospital platform</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Medical management of acute coronary syndrome</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ischaemic heart disease</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute treatment for heart failure</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ischaemic heart disease, all other cardiovascular diseases</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Early-stage cervical cancer screening and treatment</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cervix uteri cancer</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute treatment for asthma and COPD</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Chronic respiratory diseases</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" namest="col1" nameend="col2">
                           <bold>Referral and specialised hospital platform</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Percutaneous coronary intervention for acute coronary syndrome</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ischaemic heart disease</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Management of acute ventilatory failure</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Chronic respiratory diseases</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Treatment of early-stage breast cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Breast cancer</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Treatment of early-stage colorectal cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Colon cancer and rectum cancer</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="spara60" view="all">Diabetes screening and treatment includes glycaemic control (eg, oral medications and insulin as needed), foot care, and screening and treatment of albuminuric kidney disease with angiotensin blockade therapies. Cardiovascular disease preventive therapies among individuals with diabetes are analysed as part of the primary prevention for cardiovascular disease. Early-stage cervical cancer screening and treatment includes screening and treatment of precancerous lesions at health centres. Management of acute ventilatory failure focuses on severe acute exacerbations of asthma and COPD requiring either invasive or non-invasive mechanical ventilation. Specific measures for sodium reduction are specified as per the WHO sodium reduction package: product reformulation, front-of-pack labelling, information, education, and communication on discretionary salt use, and supporting an enabling environment (<ce:cross-ref id="cecref40" refid="sec1">appendix p 33</ce:cross-ref>). COPD=chronic obstructive pulmonary disease. For full descriptions of interventions, including specific types of recommended medications and procedures, see <ce:cross-ref id="cecref50" refid="sec1">appendix pp 15–34</ce:cross-ref>.</ce:simple-para>
               </ce:legend>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl2" frame="topbot" rowsep="0" colsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cecap40">
                  <ce:simple-para id="spara70" role="caption" view="all">Findings from pathway analysis: achievement of the SDG target 3.4 at the country level and regional level if all interventions are implemented</ce:simple-para>
               </ce:caption>
               <tgroup cols="5">
                  <colspec colnum="1" colname="col1"/>
                  <colspec colnum="2" colname="col2"/>
                  <colspec colnum="3" colname="col3"/>
                  <colspec colnum="4" colname="col4"/>
                  <colspec colnum="5" colname="col5"/>
                  <thead>
                     <row valign="bottom" rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Projected reduction in the probability of death from NCD4 between ages 30 and 70 years with no additional action</bold>
                           <cross-ref id="cecref60" refid="tbl2fn1">*</cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Percentage of countries achieving SDG target 3.4</bold>
                           <cross-ref id="cecref70" refid="tbl2fn2">
                              <sup loc="post">†</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Median number of clinical interventions across all countries in a region</bold>
                           <cross-ref id="cecref80" refid="tbl2fn3">
                              <sup loc="post">‡</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Percentage of countries in a region reducing NCD4 mortality by a third in the reference scenario</bold>
                           <cross-ref id="cecref90" refid="tbl2fn4">
                              <sup loc="post">§</sup>
                           </cross-ref>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Latin America and the Caribbean</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10% (5–17)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">59%</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Central and eastern Europe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">17% (15–21)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">50%</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Central Asia, the Middle East, and north Africa</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12% (11–20)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">76%</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Sub-Saharan Africa</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10% (6–24)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">45%</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">South Asia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6% (4–13)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">50%</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">East and southeast Asia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15% (8–19)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">54%</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Oceania</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10% (8–13)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">75%</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">All low-income and middle-income countries</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12% (7–19)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">55%</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="spara80" view="all">Data are % (IQR) unless otherwise specified. For a list of countries in each world region see <ce:cross-ref id="cecref100" refid="sec1">appendix p 36</ce:cross-ref>. NCD4=four main non-communicable diseases (cancer, cardiovascular diseases, chronic respiratory diseases, and diabetes). SDG=Sustainable Development Goal.</ce:simple-para>
               </ce:legend>
               <ce:table-footnote id="tbl2fn1">
                  <ce:label>*</ce:label>
                  <ce:note-para id="cenpara10" view="all">These values reflect the distribution of country-specific progress towards SDG target 3.4 in each region under a business-as-usual scenario in which no additional policy implementation or scale-up of clinical interventions occurs.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl2fn2">
                  <ce:label>†</ce:label>
                  <ce:note-para id="cenpara20" view="all">These percentages are based on our model that uses historical trends and factors in demographic shifts that could considerably hinder progress in many countries. Additionally, we used the latest mortality statistics (WHO Global Health Estimates 2019 <ce:italic>vs</ce:italic> Global Health Estimates 2016), and in the reference scenario factored in a modest disruption due to the COVID-19 pandemic (<ce:cross-ref id="cecref110" refid="sec1">appendix pp 10–12</ce:cross-ref>).</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl2fn3">
                  <ce:label>‡</ce:label>
                  <ce:note-para id="cenpara30" view="all">The effects of all six intersectoral policies are included in the analysis before modelling the effect of sequentially adding clinical interventions.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl2fn4">
                  <ce:label>§</ce:label>
                  <ce:note-para id="cenpara40" view="all">Although nearly all regions could achieve or nearly achieve the target in the aggregate (<ce:cross-ref id="cecref120" refid="sec1">appendix p 48</ce:cross-ref>), there would be a range of country-specific trajectories, with some countries surpassing the target and others not quite achieving it (<ce:cross-ref id="cecref130" refid="sec1">appendix p 49</ce:cross-ref>).</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl3" frame="topbot" rowsep="0" colsep="0">
               <ce:label>Table 3</ce:label>
               <ce:caption id="cecap50">
                  <ce:simple-para id="spara90" role="caption" view="all">Costs and benefits of achieving the Sustainable Development Goal target 3.4 through scale-up of priority non-communicable disease interventions, by world region</ce:simple-para>
               </ce:caption>
               <tgroup cols="7">
                  <colspec colnum="1" colname="col1"/>
                  <colspec colnum="2" colname="col2"/>
                  <colspec colnum="3" colname="col3"/>
                  <colspec colnum="4" colname="col4"/>
                  <colspec colnum="5" colname="col5"/>
                  <colspec colnum="6" colname="col6"/>
                  <colspec colnum="7" colname="col7"/>
                  <thead>
                     <row valign="top" rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Total cost of no additional action (billions)</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Total cost of accelerated progress (billions)</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Incremental cost (billions)</bold>
                           <cross-ref id="cecref140" refid="tbl3fn1">*</cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Total deaths averted (thousands)</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Cost per death averted</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Incremental annual cost per capita</bold>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Latin America and Caribbean</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$320</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$350</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$35</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3600</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$9800</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$6·8</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Central and aastern Europe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$160</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$170</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1900</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$6200</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$4·5</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Central Asia, the Middle East, and north Africa</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$190</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$200</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$7·0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2400</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$3000</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$1·4</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Sub-Saharan Africa</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$45</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$54</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$9·3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3400</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$2700</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$1·0</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">South Asia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$160</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$180</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14 000</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$1500</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$1·4</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">East and southeast Asia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$1000</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$1100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$57</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14 000</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$4200</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$3·3</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Oceania</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$1·1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$1·7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$0·56</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">80</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$7000</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$6·6</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">All low-income and middle-income countries</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$1900</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$2000</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$140</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">39 000</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$3600</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">$2·6</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="spara100" view="all">Costs are in 2020 US dollars. Costs and deaths averted are totals over 2023–30. Average annual costs reported in the main text are calculated by dividing these costs by 8 years. Numbers might not add up exactly due to rounding. For a list of countries in each world region see <ce:cross-ref id="cecref150" refid="sec1">appendix p 36</ce:cross-ref>.</ce:simple-para>
               </ce:legend>
               <ce:table-footnote id="tbl3fn1">
                  <ce:label>*</ce:label>
                  <ce:note-para id="cenpara50" view="all">Incremental cost is the difference of the total cost of accelerated progress and the total cost of no additional action.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl4" frame="topbot" rowsep="0" colsep="0">
               <ce:label>Table 4</ce:label>
               <ce:caption id="cecap60">
                  <ce:simple-para id="spara110" role="caption" view="all">Health system implementation requirements for priority clinical interventions for non-communicable diseases</ce:simple-para>
               </ce:caption>
               <tgroup cols="6">
                  <colspec colnum="1" colname="col1"/>
                  <colspec colnum="2" colname="col2"/>
                  <colspec colnum="3" colname="col3"/>
                  <colspec colnum="4" colname="col4"/>
                  <colspec colnum="5" colname="col5"/>
                  <colspec colnum="6" colname="col6"/>
                  <thead>
                     <row valign="top" rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Principal health worker implementing intervention</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Typical annual case volume per 100 000 population</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Complexity of case management system</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Potential for major human resource obstacles</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Potential for major drug, equipment, or facility obstacles</bold>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" namest="col1" nameend="col6">
                           <bold>Community platform</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pulmonary rehabilitation</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Allied professionals</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">45</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lower</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Higher</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lower</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" namest="col1" nameend="col6">
                           <bold>Health centre platform</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Primary prevention for cardiovascular disease</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Clinical officers</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3200</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lower</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lower</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Secondary prevention for cardiovascular disease</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Clinical officers</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2600</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Higher</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Aspirin for suspected acute coronary syndrome</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Nurses</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">170</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lower</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lower</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lower</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Chronic treatment for heart failure</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Clinical officers</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">460</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Chronic treatment for asthma and COPD</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Clinical officers</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3600</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lower</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Diabetes screening and treatment</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Clinical officers</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4300</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lower</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" namest="col1" nameend="col6">
                           <bold>First-level hospital platform</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Medical management of acute coronary syndrome</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Clinical officers</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">260</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lower</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute treatment for heart failure</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Clinical officers</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">230</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Early-stage cervical cancer treatment</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Clinical officers</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lower</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Higher</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute treatment for asthma and COPD</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Clinical officers</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">560</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" namest="col1" nameend="col6">
                           <bold>Referral and specialty hospital platform</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Percutaneous coronary intervention for acute coronary syndrome</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Specialist doctors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">45</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Higher</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Higher</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Higher</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Management of acute ventilatory failure</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Generalist doctors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">33</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Higher</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Moderate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Higher</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Treatment of early-stage breast cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Specialist doctors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Higher</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Higher</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Higher</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Treatment of early-stage colorectal cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Specialist doctors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Higher</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Higher</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Higher</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="spara120" view="all">Descriptions of the data inputs and criteria used to make these assessments are in the <ce:cross-ref id="cecref160" refid="sec1">appendix (pp 13–15)</ce:cross-ref>. The principal health worker implementing intervention is the primary provider of the main components of the intervention. The typical case volume per 100 000 population is taken from estimates of the number of persons requiring the intervention (at 100% population coverage) from the cost model used in this report. The last three columns reflect differential constraints to scale-up that might emerge if specific countries were to implement the interventions listed in <ce:cross-ref id="cecref170" refid="tbl1">table 1</ce:cross-ref> over the next 8 years. The information included in this table shows how health system capacity and anticipated barriers to scale-up might serve as an adjunct to cost-effectiveness estimates, influencing the prioritisation of different interventions in different countries. COPD=chronic obstructive pulmonary disease.</ce:simple-para>
               </ce:legend>
            </ce:table>
            <ce:textbox id="box1">
               <ce:label>Panel 1</ce:label>
               <ce:caption id="cecap70">
                  <ce:simple-para id="spara130" role="caption" view="all">Key messages</ce:simple-para>
               </ce:caption>
               <ce:textbox-body>
                  <ce:sections>
                     <ce:para id="para10" view="all">
                        <ce:list id="celist10">
                           <ce:list-item id="celistitem10">
                              <ce:label>•</ce:label>
                              <ce:para id="para20" view="all">Most low-income and middle-income countries are off track to reach SDG target 3.4 for NCD mortality. To help countries get back on track, we propose a framework for NCD investment that is centred around a model package of 21 interventions that are feasible to implement and can form the backbone of national NCD strategies.</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem20">
                              <ce:label>•</ce:label>
                              <ce:para id="para30" view="all">Implementing these interventions could result in a reduction of a third or more in mortality by 2030 for several specific NCDs, especially cardiovascular diseases. Although most of these interventions are cost-effective in nearly all world regions, national governments could further tailor this package by scaling up the most cost-effective subset of interventions that addresses the top NCD causes locally.</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem30">
                              <ce:label>•</ce:label>
                              <ce:para id="para40" view="all">Under ambitious but realistic implementation conditions, the intervention strategy would allow low-income and middle-income countries to achieve SDG target 3.4, including nearly all world regions and 55% of countries; other countries might fall short of the target because of especially unfavourable recent trends and health system constraints.</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem40">
                              <ce:label>•</ce:label>
                              <ce:para id="para50" view="all">Achieving SDG target 3.4 worldwide would require US$140 billion in new spending over 2023–30, an average of $18 billion annually, but 39 million deaths could be averted over this period and $2·7 trillion in net economic benefits could be generated, with benefits outweighing costs nineteen-to-one. These costs would comprise a considerable share of the health budget (median value of 20% by 2030); mobilisation of additional resources would be required in low-income and lower-middle-income countries.</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem50">
                              <ce:label>•</ce:label>
                              <ce:para id="para60" view="all">Although countries exhibit wide variation in NCD epidemiology and health system capacity, cross-cutting intersectoral policies on tobacco, alcohol, and unhealthy diet are relevant and essential in all countries, contribute two-thirds of the total mortality impact of the package, and can reduce need for costly clinical services.</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem60">
                              <ce:label>•</ce:label>
                              <ce:para id="para70" view="all">We conclude with a summary of non-financial challenges that health planners need to consider when developing their NCD strategies; health workforce development is among the most important of these. As such, advocates and policy makers need to have a long-term approach to NCDs that emphasises feasibility and sustainability and is aligned with national health system strengthening and universal health coverage agendas.</ce:para>
                           </ce:list-item>
                        </ce:list>
                     </ce:para>
                     <ce:para id="para80" view="all">NCDs=non-communicable diseases. SDG=Sustainable Development Goal.</ce:para>
                  </ce:sections>
               </ce:textbox-body>
            </ce:textbox>
            <ce:textbox id="box2">
               <ce:label>Panel 2</ce:label>
               <ce:caption id="cecap80">
                  <ce:simple-para id="spara140" role="caption" view="all">NCD planning and resource mobilisation challenges in Malawi</ce:simple-para>
               </ce:caption>
               <ce:textbox-body>
                  <ce:sections>
                     <ce:para id="para90" view="all">Several studies have shown that Malawi has a limited ability to mobilise domestic resources for health. The health budget remains dependent on external aid, with a small margin for reallocation of funds to different programmatic areas. A 2018 resource mapping exercise found that 75% of health sector resources are contributed by 189 external donors,<ce:cross-ref id="cecref180" refid="bib30">
                           <ce:sup loc="post">30</ce:sup>
                        </ce:cross-ref> each with their own health priorities and budgets, mostly for communicable, maternal, neonatal, and nutritional diseases. NCDs received less than US$2 million of the $693 million budgeted for the 2017–18 fiscal year, with half the funds coming from donors.</ce:para>
                     <ce:para id="para100" view="all">Like many countries without vital registration systems,<ce:cross-ref id="cecref190" refid="bib31">
                           <ce:sup loc="post">31</ce:sup>
                        </ce:cross-ref> estimates of cause-specific mortality in Malawi are based on models that use data from other countries. According to WHO data, simply maintaining the 2015–19 rate of decline in the probability of death from NCD4 between ages 30 and 70 years would result in a 31% reduction by 2030, very close to SDG target 3.4. This puts local planners in a conundrum: are the WHO estimates reliable? If so, should the government even focus on NCDs when there are many other pressing concerns? If not, how can a government hedge its bets, investing strategically in NCDs while not diverting resources from successful vertical programmes?</ce:para>
                     <ce:para id="para110" view="all">According to our pathway analysis, Malawi could achieve SDG target 3.4 using only the intersectoral policies (<ce:cross-ref id="cecref200" refid="tbl1">table 1</ce:cross-ref>), none of which have been fully implemented to date. The costs of this strategy would be modest (about $8000 annually for policy monitoring and enforcement). However, if there is insufficient political will to implement tobacco and alcohol policies, the country could achieve SDG target 3.4 by expanding the three most cost-effective clinical interventions to an additional 20% of the population (<ce:cross-ref id="cecref210" refid="sec1">appendix p 42</ce:cross-ref>). This approach would cost an additional $4·5 million in total over 2023–30 ($560 000 per year) but could avert 3000 deaths ($1500 per death averted) and 54 000 DALYs ($83 per averted DALY) and begin to expand primary health-care capacity to respond to NCDs.</ce:para>
                     <ce:para id="para120" view="all">We conclude that one of the most urgent priorities for the NCD agenda in Malawi—and many other countries—is collection of local data on causes of death so that policy makers do not run the risk of being falsely reassured by (modelled) global health estimates. Beyond better measurement, implementation of tobacco and alcohol control policies and a small set of primary health-care interventions, initially at a reduced coverage, is likely to be feasible and will allow the country to make strides on NCDs in the face of considerable fiscal challenges.</ce:para>
                     <ce:para id="para130" view="all">NCDs=non-communicable diseases. NCD4=four main non-communicable diseases (cancer, cardiovascular diseases, chronic respiratory diseases, and diabetes). SDG=Sustainable Development Goal.</ce:para>
                  </ce:sections>
               </ce:textbox-body>
            </ce:textbox>
            <ce:textbox id="box3">
               <ce:label>Panel 3</ce:label>
               <ce:caption id="cecap90">
                  <ce:simple-para id="spara150" role="caption" view="all">Priority-setting for NCDs in Ethiopia</ce:simple-para>
               </ce:caption>
               <ce:textbox-body>
                  <ce:sections>
                     <ce:para id="para140" view="all">NCDs are quickly becoming a major health issue in Ethiopia: the proportion of total deaths due to NCDs increased from 19% in 2000 to 37% in 2017.<ce:cross-ref id="cecref220" refid="bib42">
                           <ce:sup loc="post">42</ce:sup>
                        </ce:cross-ref> Surveys have found that nearly all adults have at least one NCD risk factor, although the specific risk factors and their magnitude vary between urban and rural settings.<ce:cross-ref id="cecref230" refid="bib43">
                           <ce:sup loc="post">43</ce:sup>
                        </ce:cross-ref> Coverage of essential NCD interventions range from 5% to 10%, and more than 90% of health centres and hospitals do not have adequate human resources for managing NCDs.<ce:cross-ref id="cecref240" refid="bib44">
                           <ce:sup loc="post">44</ce:sup>
                        </ce:cross-ref> Only 11% of total health expenditure (US$33 per capita in 2017) is spent on NCDs, with 60% of costs paid out-of-pocket.<ce:cross-refs id="cecrefs10" refid="bib45 bib46">
                           <ce:sup loc="post">45,46</ce:sup>
                        </ce:cross-refs>
                     </ce:para>
                     <ce:para id="para150" view="all">Ethiopia's 2019 Essential Health Services Package<ce:cross-ref id="cecref250" refid="bib41">
                           <ce:sup loc="post">41</ce:sup>
                        </ce:cross-ref> emphasised the growing burden of NCDs and their risk factors, which were generally neglected in previous health sector strategies.<ce:cross-ref id="cecref260" refid="bib47">
                           <ce:sup loc="post">47</ce:sup>
                        </ce:cross-ref> The Package serves to rationalise NCD investment, particularly in advanced care. For example, it includes several services for high-burden cancers, and it categorises each as high, medium, or low priority. In the case of oesophageal cancer, endoscopic and pathological diagnosis is given high priority, multimodal treatment of oesophageal cancer is given low priority (due to high cost and low effectiveness), and tobacco and alcohol cessation interventions to prevent oesophageal and other cancers are given high or medium priority. Explicitly prioritising different components of oesophageal cancer care while emphasising the value of risk reduction and the need to focus scarce resources on risk reduction and diagnosis and surveillance ensures that the condition is not neglected altogether; this prioritisation scheme can be reassessed as more resources become available and the Essential Health Services Package is revised.</ce:para>
                     <ce:para id="para160" view="all">Unfortunately, because of budget shortfalls and the need to address the priorities of global health initiatives, the medium-priority NCD interventions in the Package are offered only on a cost-sharing basis, and the low-priority NCD interventions are offered only on a full cost-recovery basis. Given development partners’ weaker engagement on NCDs, and insufficient public resources, the financial responsibility for achieving Sustainable Development Goal target 3.4 in Ethiopia will probably fall largely on patients.</ce:para>
                     <ce:para id="para170" view="all">NCDs=non-communicable diseases.</ce:para>
                  </ce:sections>
               </ce:textbox-body>
            </ce:textbox>
         </ce:floats>
         <head>
            <ce:dochead id="cedoch10">
               <ce:textfn>Health Policy</ce:textfn>
            </ce:dochead>
            <ce:title id="cetitle10">NCD Countdown 2030: efficient pathways and strategic investments to accelerate progress towards the Sustainable Development Goal target 3.4 in low-income and middle-income countries</ce:title>
            <ce:author-group id="aug10">
               <ce:collaboration id="cecollab10" collaboration-id="S0140673621023473-8fdaaec46590af5404f6f5406aff8e26">
                  <ce:text>NCD Countdown 2030 collaborators</ce:text>
                  <ce:cross-ref id="cecref270" refid="fn1">
                     <ce:sup loc="post">†</ce:sup>
                  </ce:cross-ref>
                  <ce:author-group id="aug20">
                     <ce:author id="au10" author-id="S0140673621023473-716fa24d8306ea70480bf1d89ea29089">
                        <ce:given-name>David A</ce:given-name>
                        <ce:surname>Watkins</ce:surname>
                     </ce:author>
                     <ce:author id="au20" author-id="S0140673621023473-64df4fc7f24f3e49e5dbc0c110f78df9">
                        <ce:given-name>William T</ce:given-name>
                        <ce:surname>Msemburi</ce:surname>
                     </ce:author>
                     <ce:author id="au30" author-id="S0140673621023473-b2b3934fc6bf22be23e96d37976c20a3">
                        <ce:given-name>Sarah J</ce:given-name>
                        <ce:surname>Pickersgill</ce:surname>
                     </ce:author>
                     <ce:author id="au40" author-id="S0140673621023473-bb95f171a8cb456071a2eb472cf8e26b">
                        <ce:given-name>Yoshito</ce:given-name>
                        <ce:surname>Kawakatsu</ce:surname>
                     </ce:author>
                     <ce:author id="au50" author-id="S0140673621023473-09224b3f1de7b990ed2db327dfd8b423">
                        <ce:given-name>Adrian</ce:given-name>
                        <ce:surname>Gheorghe</ce:surname>
                     </ce:author>
                     <ce:author id="au60" author-id="S0140673621023473-203e6cb1d31939fb93c08adfa71bdeb4">
                        <ce:given-name>Katie</ce:given-name>
                        <ce:surname>Dain</ce:surname>
                     </ce:author>
                     <ce:author id="au70" author-id="S0140673621023473-7f4a672ebd3030edc6e20cad9bad2d96">
                        <ce:given-name>Kjell Arne</ce:given-name>
                        <ce:surname>Johansson</ce:surname>
                     </ce:author>
                     <ce:author id="au80" author-id="S0140673621023473-b15ad9b4a0dcbcbc49d53ba88de077c3">
                        <ce:given-name>Sanaa</ce:given-name>
                        <ce:surname>Said</ce:surname>
                     </ce:author>
                     <ce:author id="au90" author-id="S0140673621023473-7f04e8735c20201fe74c8eb2c3f76165">
                        <ce:given-name>Nina</ce:given-name>
                        <ce:surname>Renshaw</ce:surname>
                     </ce:author>
                     <ce:author id="au100" author-id="S0140673621023473-84fca73fb4eb72bb9282ba6d762c46fb">
                        <ce:given-name>Mieraf T</ce:given-name>
                        <ce:surname>Tolla</ce:surname>
                     </ce:author>
                     <ce:author id="au110" author-id="S0140673621023473-246171baaa3f242c9f746e352c9cb8b1">
                        <ce:given-name>Pakwanja D</ce:given-name>
                        <ce:surname>Twea</ce:surname>
                     </ce:author>
                     <ce:author id="au120" author-id="S0140673621023473-5d94275a7753714784c24b03b88db6b4">
                        <ce:given-name>Cherian</ce:given-name>
                        <ce:surname>Varghese</ce:surname>
                     </ce:author>
                     <ce:author id="au130" author-id="S0140673621023473-8112d1f6841ec460f5153c3067c45080">
                        <ce:given-name>Kalipso</ce:given-name>
                        <ce:surname>Chalkidou</ce:surname>
                     </ce:author>
                     <ce:author id="au140" author-id="S0140673621023473-e457ff845facd8cfe6054bfa07ecc461">
                        <ce:given-name>Majid</ce:given-name>
                        <ce:surname>Ezzati</ce:surname>
                     </ce:author>
                     <ce:author id="au150" author-id="S0140673621023473-f99d1a3b43968bccd7f7295ed565cc90">
                        <ce:given-name>Ole Frithjof</ce:given-name>
                        <ce:surname>Norheim</ce:surname>
                     </ce:author>
                  </ce:author-group>
               </ce:collaboration>
               <ce:footnote id="fn1">
                  <ce:label>†</ce:label>
                  <ce:note-para id="cenpara60" view="all">Collaborators listed at the end of the paper</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:abstract id="ceab10" view="all" class="author"><ce:abstract-sec id="ceabs10" view="all">
                  <ce:simple-para id="spara160" view="all">Most countries have made little progress in achieving the Sustainable Development Goal (SDG) target 3.4, which calls for a reduction in premature mortality from non-communicable diseases (NCDs) by a third from 2015 to 2030. In this Health Policy paper, we synthesise the evidence related to interventions that can reduce premature mortality from the major NCDs over the next decade and that are feasible to implement in countries at all levels of income. Our recommendations are intended as generic guidance to help 123 low-income and middle-income countries meet SDG target 3.4; country-level applications require additional analyses and consideration of the local implementation and utilisation context. Protecting current investments and scaling up these interventions is especially crucial in the context of COVID-19-related health system disruptions. We show how cost-effectiveness data and other information can be used to define locally tailored packages of interventions to accelerate rates of decline in NCD mortality. Under realistic implementation constraints, most countries could achieve (or almost achieve) the NCD target using a combination of these interventions; the greatest gains would be for cardiovascular disease mortality. Implementing the most efficient package of interventions in each world region would require, on average, an additional US$18 billion annually over 2023–30; this investment could avert 39 million deaths and generate an average net economic benefit of $2·7 trillion, or $390 per capita. Although specific clinical intervention pathways would vary across countries and regions, policies to reduce behavioural risks, such as tobacco smoking, harmful use of alcohol, and excess sodium intake, would be relevant in nearly every country, accounting for nearly two-thirds of the health gains of any locally tailored NCD package. By 2030, ministries of health would need to contribute about 20% of their budgets to high-priority NCD interventions. Our report concludes with a discussion of financing and health system implementation considerations and reflections on the NCD agenda beyond the SDG target 3.4 and beyond the SDG period.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="cesec10" view="all">
                  <ce:section-title id="cestitle20">Introduction</ce:section-title>
                  <ce:para id="para180" view="all">The UN Sustainable Development Goal (SDG) target 3.4 calls for all Member States to reduce premature mortality from non-communicable diseases (NCDs) by a third between 2015 and 2030.<ce:cross-ref id="cecref280" refid="bib1">
                        <ce:sup loc="post">1</ce:sup>
                     </ce:cross-ref> Some countries have made progress on NCDs in recent decades by scaling up evidence-based therapies, such as drugs for secondary prevention of cardiovascular disease, and targeting risk factors, such as smoking and raised blood pressure.<ce:cross-refs id="cecrefs20" refid="bib2 bib3">
                        <ce:sup loc="post">2,3</ce:sup>
                     </ce:cross-refs> However, in a deviation from historical trends, reductions in death rates caused by NCDs have been decelerating since 2010; in some countries, rates have increased.<ce:cross-ref id="cecref290" refid="bib4">
                        <ce:sup loc="post">4</ce:sup>
                     </ce:cross-ref> Before the COVID-19 pandemic, most countries were off track in achieving SDG target 3.4.<ce:cross-refs id="cecrefs30" refid="bib5 bib6">
                        <ce:sup loc="post">5,6</ce:sup>
                     </ce:cross-refs>
                  </ce:para>
                  <ce:para id="para190" view="all">NCDs encompass a broad range of conditions, and there is no universal strategy for meeting SDG target 3.4. In 2020, the NCD Countdown 2030 Collaborators identified a range of epidemiological pathways for countries to achieve SDG target 3.4.<ce:cross-ref id="cecref300" refid="bib6">
                        <ce:sup loc="post">6</ce:sup>
                     </ce:cross-ref> For example, historical rates of decline in tobacco-related cancer deaths among women are generally sufficient for achieving the target in sub-Saharan African countries, but not in high-income European countries. These findings suggest that countries could achieve the target by considering trends in locally relevant NCDs and selecting interventions that quickly reduce cause-specific mortality. Unfortunately, the COVID-19 pandemic has upended national NCD programmes.<ce:cross-ref id="cecref310" refid="bib7">
                        <ce:sup loc="post">7</ce:sup>
                     </ce:cross-ref> People living with NCDs have been especially affected, often with higher complication rates from infection<ce:cross-refs id="cecrefs40" refid="bib8 bib9 bib10">
                        <ce:sup loc="post">8–10</ce:sup>
                     </ce:cross-refs> and disruptions in NCD care, leading to excess mortality.<ce:cross-ref id="cecref320" refid="bib11">
                        <ce:sup loc="post">11</ce:sup>
                     </ce:cross-ref> As efforts to roll out COVID-19 vaccines accelerate, policy makers and planners will need concrete guidance for making progress on SDG target 3.4—often with overstretched health systems and fewer resources than before the pandemic.</ce:para>
                  <ce:para id="para200" view="all">In this Health Policy, we present evidence on the types of interventions that can help achieve SDG target 3.4 in different settings, and the resources required to implement these interventions (<ce:cross-ref id="cecref330" refid="box1">panel 1</ce:cross-ref>
                     <ce:float-anchor refid="box1"/>). Our work serves as a starting point for country-specific analyses to inform planning, financing, and implementation. We focus on the later years of the SDG period (2023–30) and on the 123 countries currently classified as low-income and middle-income countries (LMICs), grouped into seven regions used in previous reports. Our report builds on earlier Countdown reports<ce:cross-refs id="cecrefs50" refid="bib5 bib6">
                        <ce:sup loc="post">5,6</ce:sup>
                     </ce:cross-refs> and includes demographic and epidemiological estimates that have been published since 2020. Our analyses are accompanied by discussion of implementation challenges and opportunities. We contend that focused scale-up of a small set of cost-effective and feasible interventions will help countries build back better, creating a sustainable foundation for a more ambitious NCD agenda in the decades to come.</ce:para>
               </ce:section>
               <ce:section id="cesec20" view="all">
                  <ce:section-title id="cestitle30">Identifying candidate interventions</ce:section-title>
                  <ce:para id="para210" view="all">The interventions to help meet SDG target 3.4 are adapted from the Disease Control Priorities Project.<ce:cross-refs id="cecrefs60" refid="bib12 bib13 bib14">
                        <ce:sup loc="post">12–14</ce:sup>
                     </ce:cross-refs> The third and most recent edition of Disease Control Priorities (DCP3) included nine volumes published over 2015–18. DCP3 volume 3 on cancer, and DCP3 volume 5 on cardiovascular, respiratory, and related disorders, had model lists of interventions that provided good value for money (usually related to cost-effectiveness), were feasible to implement in LMICs, and addressed a considerable disease burden. Recommendations from DCP3 were peer-reviewed in a process overseen by the US National Academies of Sciences, Engineering, and Medicine,<ce:cross-ref id="cecref340" refid="bib14">
                        <ce:sup loc="post">14</ce:sup>
                     </ce:cross-ref> and key findings were summarised in previous reviews.<ce:cross-refs id="cecrefs70" refid="bib15 bib16">
                        <ce:sup loc="post">15,16</ce:sup>
                     </ce:cross-refs>
                  </ce:para>
                  <ce:para id="para220" view="all">We reviewed the DCP3 lists for any interventions that addressed mortality from the four main types of NCDs (referred to as NCD4 hereafter): cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes (including chronic kidney disease due to diabetes). We identified 21 interventions that DCP3 recommended as essential (ie, cost-effective, feasible, and relevant) and could help countries achieve SDG target 3.4 (<ce:cross-ref id="cecref350" refid="tbl1">table 1</ce:cross-ref>
                     <ce:float-anchor refid="tbl1"/>), including 15 clinical interventions and six intersectoral policies. The intersectoral policies are population-based policies that are linked to non-health ministries (eg, taxes) but have substantial health benefits.</ce:para>
                  <ce:para id="para230" view="all">We compared our intervention list to the WHO Global Action Plan on Non-Communicable Diseases.<ce:cross-ref id="cecref360" refid="bib17">
                        <ce:sup loc="post">17</ce:sup>
                     </ce:cross-ref> Our list was fully aligned with WHO's best buys but included several additional clinical interventions, including basic treatments for acute cardiovascular and pulmonary complications, some of which were mentioned in WHO documents. DCP3 also included many interventions, such as rehabilitation and palliative care, that address non-fatal NCD outcomes.<ce:cross-refs id="cecrefs80" refid="bib14 bib18">
                        <ce:sup loc="post">14,18</ce:sup>
                     </ce:cross-refs> We note that mental health and wellbeing are included in SDG target 3.4, and self-harm mortality is used as an indicator. Interventions to address mental disorders and reduce self-harm are not discussed in this report, but NCD and mental health strategies are tightly linked, including shared delivery (through primary health care), shared risk factors such as alcohol use, and comorbidity (eg, treatment of depression among persons with NCDs).</ce:para>
                  <ce:para id="para240" view="all">The metric of SDG target 3.4, which is the probability of death from NCD4 between ages 30 and 70 years, excludes deaths of people younger than 30 years and deaths that might be averted after 2030; therefore, interventions, such as treatment of childhood cancers and human papillomavirus immunisation, were not considered for further analysis. These interventions are crucial to national NCD strategies and universal health coverage (UHC) benefits packages, even though they do not contribute to the target. Limitations of the target and implications for the NCD agenda are also discussed in this report.</ce:para>
                  <ce:para id="para250" view="all">The 21 interventions are a subset of all the options for reducing NCD4 mortality (<ce:cross-ref id="cecref370" refid="tbl1">table 1</ce:cross-ref>). For instance, DCP3 and WHO do not include multimodal treatment of oesophageal cancer in their lists, although some countries might already be offering this intervention, and it might be important in countries with a high prevalence of oral tobacco use or alcohol drinking. <ce:cross-ref id="cecref380" refid="tbl1">Table 1</ce:cross-ref> serves as a model package, reflecting the essentials of NCD4 prevention and treatment that merit special consideration and preferential scale-up. Additional interventions will be relevant in countries with well resourced health systems.</ce:para>
               </ce:section>
               <ce:section id="cesec30" view="all">
                  <ce:section-title id="cestitle40">Prospects for reducing mortality from specific NCDs</ce:section-title>
                  <ce:para id="para260" view="all">Worldwide, NCD4 mortality has not decreased quickly enough to reach SDG target 3.4, and some specific causes and risks, such as diabetes and obesity, are increasing, leading to diverging outcomes and increasing inequality across countries.<ce:cross-ref id="cecref390" refid="bib4">
                        <ce:sup loc="post">4</ce:sup>
                     </ce:cross-ref> Building on the previous Countdown reports,<ce:cross-refs id="cecrefs90" refid="bib5 bib6">
                        <ce:sup loc="post">5,6</ce:sup>
                     </ce:cross-refs> and using mortality estimates that have since become available,<ce:cross-ref id="cecref400" refid="bib19">
                        <ce:sup loc="post">19</ce:sup>
                     </ce:cross-ref> we modelled the effect of our interventions on cause-specific and sex-specific mortality by 2030 (<ce:cross-ref id="cecref410" refid="sec1">appendix pp 4–7</ce:cross-ref>). The purpose of this exercise was to understand whether the interventions could help countries meet SDG target 3.4 and to reduce mortality by a third in each specific NCD4. As such, we modelled the effects by instantly increasing the coverage of all interventions to 90% in 2023 and sustaining this coverage level through 2030 (<ce:cross-ref id="cecref420" refid="sec1">appendix p 37</ce:cross-ref>).</ce:para>
                  <ce:para id="para270" view="all">
                     <ce:cross-ref id="cecref430" refid="fig1">Figure 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/> shows the global distribution of country-specific rates of decline for both men and women for each NCD4 cause, comparing historical annualised rates of change to rates that would be realised over 2015–30 with full implementation starting in 2023. The figure shows that the interventions would drastically accelerate NCD4 mortality reduction, allowing 90% of countries to achieve the target. The greatest acceleration would be for ischaemic heart disease, with the lowest acceleration for stomach and liver cancer, because interventions for these cancers would be limited to tobacco and alcohol reduction.</ce:para>
                  <ce:para id="para280" view="all">The health benefits of behavioural risk reduction accumulate over many years. For example, Kontis and colleagues<ce:cross-ref id="cecref440" refid="bib20">
                        <ce:sup loc="post">20</ce:sup>
                     </ce:cross-ref> estimated that eliminating excess risk for chronic respiratory diseases from smoking requires 30–40 years of cessation. These delayed effects are factored into our estimates of potential mortality reduction by 2030 (<ce:cross-ref id="cecref450" refid="sec1">appendix p 45</ce:cross-ref>). Although the health effect of implementing the six intersectoral policies between now and 2030 is sufficient to justify urgent action, it is a subset of the health gains that will accrue as successive cohorts of younger individuals experience lower lifetime risk.<ce:cross-ref id="cecref460" refid="bib21">
                        <ce:sup loc="post">21</ce:sup>
                     </ce:cross-ref>
                  </ce:para>
               </ce:section>
               <ce:section id="cesec40" view="all">
                  <ce:section-title id="cestitle50">Cost-effectiveness considerations</ce:section-title>
                  <ce:para id="para290" view="all">Because health resources are scarce, many policy makers rely on cost-effectiveness information to set priorities. We analysed the cost-effectiveness of each of our 15 clinical interventions, including variations across world regions (<ce:cross-ref id="cecref470" refid="sec1">appendix pp 7–9</ce:cross-ref>). We modelled the health effects and costs of instantly increasing the coverage of each intervention by 10% in 2023 and sustaining this higher coverage through to 2030 (<ce:cross-ref id="cecref480" refid="sec1">appendix p 37</ce:cross-ref>). The rationale for modelling a small change in coverage was to allow for comparability of cost-effectiveness ratios across interventions and countries with different baseline coverage. We used the Disease Control Priorities Cost Model<ce:cross-ref id="cecref490" refid="bib22">
                        <ce:sup loc="post">22</ce:sup>
                     </ce:cross-ref> to calculate costs from the health-care sector perspective in 2020 US dollars.</ce:para>
                  <ce:para id="para300" view="all">We defined cost-effectiveness here as the percentage reduction in the probability of death from NCD4 between ages 30 and 70 years per million US dollars spent on each intervention. We used this metric instead of the cost per averted disability-adjusted life-year (DALY) because we were looking specifically at the comparative efficiency of the interventions at achieving SDG target 3.4. In a secondary analysis, we calculated intervention costs per averted DALY; the two metrics were highly correlated for our interventions (<ce:cross-ref id="cecref500" refid="sec1">appendix p 46</ce:cross-ref>).</ce:para>
                  <ce:para id="para310" view="all">We do not report cost-effectiveness ratios for the six intersectoral policies. Most of the costs of these policies are borne outside the health sector and by non-government actors (ie, private enterprises and households), so cost-effectiveness ratios based on health-care sector costs are incomplete. It was outside the scope of this report to conduct benefit-cost analyses of these policies from the societal perspective.<ce:cross-ref id="cecref510" refid="bib23">
                        <ce:sup loc="post">23</ce:sup>
                     </ce:cross-ref> The mortality impact of these policies is reflected in the other analyses in this report.</ce:para>
                  <ce:para id="para320" view="all">The cost-effectiveness findings show that there was a high consistency in comparative cost-effectiveness across regions, with most interventions differing by two to four ranks across regions (<ce:cross-ref id="cecref520" refid="fig2">figure 2</ce:cross-ref>
                     <ce:float-anchor refid="fig2"/>). For example, the ranks for primary prevention of cardiovascular disease ranged from four to six and for treatment of early-stage breast cancer from two to six. A league table for these interventions for all LMICs in the aggregate are in the <ce:cross-ref id="cecref530" refid="sec1">appendix (p 38)</ce:cross-ref>.</ce:para>
                  <ce:para id="para330" view="all">For policy makers who are more familiar with cost-per-DALY estimates, <ce:cross-ref id="cecref540" refid="fig2">figure 2</ce:cross-ref> also colour-codes each intervention according to its cost per averted DALY as a proportion of gross domestic product (GDP) per capita. On average, 14 of 15 interventions were below the upper threshold implied by the value of a life-year estimated by the <ce:italic>Lancet</ce:italic> Commission on Investing in Health (2·3 times GDP per capita),<ce:cross-ref id="cecref550" refid="bib24">
                        <ce:sup loc="post">24</ce:sup>
                     </ce:cross-ref> which is liberal, and ten interventions were below the health opportunity cost threshold estimated by Claxton and colleagues (0·5 times GDP per capita),<ce:cross-ref id="cecref560" refid="bib25">
                        <ce:sup loc="post">25</ce:sup>
                     </ce:cross-ref> the most conservative threshold proposed in the literature.</ce:para>
               </ce:section>
               <ce:section id="cesec50" view="all">
                  <ce:section-title id="cestitle60">Efficient pathways to achieving SDG target 3.4</ce:section-title>
                  <ce:para id="para340" view="all">For most countries, achieving 90% coverage of all the interventions in this package by 2023 (<ce:cross-ref id="cecref570" refid="fig1">figure 1</ce:cross-ref>) will be unrealistic. Countries that are closer to reaching SDG target 3.4 might not need to scale up all interventions during the SDG period, allowing them to direct scarce resources to other health objectives. We next identified locally tailored packages that would selectively implement these interventions in different settings based on local cost-effectiveness rankings. Within our population model, we developed an algorithm that sequentially added interventions in order of decreasing cost-effectiveness until the target reduction in the probability of death from NCD4 between ages 30 and 70 years was achieved, or until all interventions had been implemented (<ce:cross-ref id="cecref580" refid="sec1">appendix pp 10–11</ce:cross-ref>). This exercise identified the pathway that would allow each country to achieve the SDG target 3.4 at the lowest cost. Our model included the effects and (health-care sector) costs of fully implementing all six intersectoral policies by 2025.</ce:para>
                  <ce:para id="para350" view="all">We found that the number of interventions required to reach the SDG target varied considerably, although the median number across all LMICs was 12 of 15 clinical interventions, once all six intersectoral policies were implemented (<ce:cross-ref id="cecref590" refid="tbl2">table 2</ce:cross-ref>
                     <ce:float-anchor refid="tbl2"/>). The total number of deaths from NCD4 between ages 30 and 70 years across all 123 LMICs would be reduced by 35%, and all regions except Latin America and the Caribbean and Oceania would achieve the target (<ce:cross-ref id="cecref600" refid="sec1">appendix p 48</ce:cross-ref>), although several countries in each region would not be able to achieve the target, ranging from 24% in central Asia, the Middle East, and north Africa to 55% in sub-Saharan Africa (<ce:cross-ref id="cecref610" refid="tbl2">table 2</ce:cross-ref>; <ce:cross-ref id="cecref620" refid="sec1">appendix p 49</ce:cross-ref>). Notably, countries that could not achieve the requisite reduction of a third in mortality would still experience considerable accelerations in rates of decline in cause-specific mortality (<ce:cross-ref id="cecref630" refid="sec1">appendix p 50</ce:cross-ref>).</ce:para>
                  <ce:para id="para360" view="all">Cardiovascular disease interventions featured prominently in our algorithm, in part because ischaemic heart disease and stroke are the biggest causes of NCD4 mortality in nearly every country, and the intervention effects occur relatively quickly. Across all LMICs, the interventions with the lowest median rank in the pathway analyses (ie, first to be incorporated by the algorithm) were aspirin for suspected acute coronary syndrome, chronic heart failure treatment, cardiovascular disease primary prevention, and treatment of early-stage breast cancer (<ce:cross-ref id="cecref640" refid="sec1">appendix p 39</ce:cross-ref>). Glycaemic control in diabetes was less cost-effective than most other interventions, but diabetes management has substantial co-benefits when deployed alongside cardiovascular disease prevention. Because of insufficient data, we did not incorporate economies of scope for different combinations of interventions in our model, but these efficiencies would be important to consider in country-level policy applications. Notably, most of the mortality benefit from diabetes care comes from cardiovascular risk reduction rather than glycaemic control;<ce:cross-ref id="cecref650" refid="bib26">
                        <ce:sup loc="post">26</ce:sup>
                     </ce:cross-ref> our analyses included cardiovascular risk management in people with diabetes as part of cardiovascular disease primary prevention.</ce:para>
                  <ce:para id="para370" view="all">We identified two particularly important unknowns in our analysis. The first was the temporary increase in NCD4 mortality rates during the pandemic, which would affect our demographic projections and trends in the probability of death from NCD4 between ages 30 and 70 years. The second was the rate at which countries could scale up the interventions starting in 2023. We did a series of scenario analyses reflecting best-case to worst-case values of these two parameters (<ce:cross-ref id="cecref660" refid="sec1">appendix p 47</ce:cross-ref>). We identified a range of five plausible values for each of these two parameters (<ce:cross-ref id="cecref670" refid="sec1">appendix pp 11–12</ce:cross-ref>) and ran our pathway analysis 25 times; estimates presented in this report are for the reference scenario only (<ce:cross-ref id="cecref680" refid="sec1">appendix p 51</ce:cross-ref>).</ce:para>
                  <ce:para id="para380" view="all">We found that the excess NCD4 mortality from COVID-19 would probably not, in a strictly epidemio-logical sense, affect achievement of SDG target 3.4, since it would not directly result in long-term changes in age-specific death rates. However, local control of the pandemic matters greatly: all else equal, a larger shock from the COVID-19 pandemic would result in a greater number of NCD4 deaths during the pandemic (<ce:cross-ref id="cecref690" refid="sec1">appendix p 51</ce:cross-ref>). The rate at which the NCD4 interventions can be scaled up (<ce:cross-ref id="cecref700" refid="sec1">appendix p 51</ce:cross-ref>) would determine the likelihood of achieving the target. This rate could be influenced by COVID-19-related health system collapse, or the strengthening of NCD investments. If new technologies, implementation strategies, and policies could be developed to scale these interventions at the same rate as vertical HIV/AIDS and immunisation programmes (historically, around 4–5% per year, as compared to the 2·5% per year assumed in our reference scenario), 83% of countries could achieve the target.</ce:para>
               </ce:section>
               <ce:section id="cesec60" view="all">
                  <ce:section-title id="cestitle70">Costs and benefits of achieving SDG target 3.4</ce:section-title>
                  <ce:para id="para390" view="all">We next estimated the increase in spending (incremental cost) required in the reference scenario and the resulting health and economic gains. To do this, we subtracted the costs of maintaining interventions at their current coverage levels (ie, no additional action) from the total costs of scale-up, giving the incremental costs. We estimated the number of deaths in the reference scenario and subtracted these from projections of cause-specific mortality if no additional action were taken (<ce:cross-ref id="cecref710" refid="sec1">appendix, pp 4–6</ce:cross-ref>), giving the number of deaths averted.</ce:para>
                  <ce:para id="para400" view="all">Over 2023–30, the total investment implied in the reference scenario would be US$2·0 trillion, averaging about $253 billion annually across all LMICs, which is $18 billion higher annually than simply maintaining current coverage ($235 billion annually). Across all LMICs, the per-capita annual incremental cost would be $2·6 on average, representing an additional 0·6% of current gross national income per capita. Regional costs would vary widely, and since each region is comprised of countries with a range of income levels and health-care prices, per-capita costs would be lower-than-average in a region's low-income countries (LICs) and higher in its upper-middle-income countries.</ce:para>
                  <ce:para id="para410" view="all">In the reference scenario, 39 million deaths could be averted across all LMICs over 2023–30 (<ce:cross-ref id="cecref720" refid="tbl3">table 3</ce:cross-ref>
                     <ce:float-anchor refid="tbl3"/>). The overall cost per death averted would be $3600. Using standard methods for valuing mortality risk reduction,<ce:cross-ref id="cecref730" refid="bib27">
                        <ce:sup loc="post">27</ce:sup>
                     </ce:cross-ref> we calculated the net economic benefits—ie, economic value of reduced mortality less intervention cost—of achieving the target and benefit–cost ratios. Worldwide, the net benefits would be $2·7 trillion ($390 per capita), roughly 19 times the incremental cost. Net benefits and benefit-cost ratios would vary considerably, although the investments would be very cost-beneficial in all regions (<ce:cross-ref id="cecref740" refid="sec1">appendix p 41</ce:cross-ref>). Our economic analysis shows that, even if some countries could not achieve SDG target 3.4 because of logistical constraints, they would still yield considerable returns and build capacity to do more on NCDs as resources permit.</ce:para>
               </ce:section>
               <ce:section id="cesec70" view="all">
                  <ce:section-title id="cestitle80">Domestic financing to achieve SDG target 3.4</ce:section-title>
                  <ce:para id="para420" view="all">US$18 billion annually in new spending to achieve SDG target 3.4 worldwide would be a relatively small sum compared with the size of the overall health economy of these countries ($890 billion). It would also be lower than the additional annual spending needed to finance a comprehensive set of NCD and injury interventions in LICs and lower-middle-income countries ($72 billion, in 2012 US$)<ce:cross-ref id="cecref750" refid="bib18">
                        <ce:sup loc="post">18</ce:sup>
                     </ce:cross-ref> and the additional spending required to achieve all the health SDGs across 67 LMICs ($274 billion, in 2014 US$).<ce:cross-ref id="cecref760" refid="bib28">
                        <ce:sup loc="post">28</ce:sup>
                     </ce:cross-ref> Some countries would still struggle to finance a basic NCD package through domestic resources alone. Studies before the COVID-19 pandemic that looked at UHC and SDG financing found that LICs, and some lower-middle-income countries, face substantial budgetary shortfalls.<ce:cross-refs id="cecrefs100" refid="bib28 bib29">
                        <ce:sup loc="post">28,29</ce:sup>
                     </ce:cross-refs> Countries whose economic growth has been disproportionately affected by the pandemic, such as tourism-dependent LICs, could be drastically affected.</ce:para>
                  <ce:para id="para430" view="all">To explore the affordability of our package in different world regions, we used WHO National Health Accounts data and macroeconomic projections from the International Monetary Fund to estimate annual growth in health budgets through 2030. These projections factored in the medium-term macroeconomic effect of the COVID-19 pandemic; we made conservative assumptions about medium-term growth in the health budget using historical trends (<ce:cross-ref id="cecref770" refid="sec1">appendix pp 12–13</ce:cross-ref>). For the median country, the total cost of implementing the locally tailored package would need to be approximately 20% of government health expenditure by 2030 (<ce:cross-ref id="cecref780" refid="sec1">appendix p 53</ce:cross-ref>). This estimate includes the costs of scaling up the higher-priority interventions (in the pathway analysis) and the costs of maintaining the other interventions (<ce:cross-ref id="cecref790" refid="tbl1">table 1</ce:cross-ref>) at their current coverage.</ce:para>
                  <ce:para id="para440" view="all">For some middle-income countries, spending 20% of the health budget to achieve SDG target 3.4 might be a reasonable proposition, particularly considering their higher NCD burden and level of health system resources overall. Other countries, especially LICs, face challenges in raising sufficient new revenues for their new NCD programmes. The situation is particularly acute in heavily aid-dependent countries with an outsized influence of global health initiatives. Some countries, such as Malawi, could achieve considerable mortality reductions at relatively low cost (<ce:cross-ref id="cecref800" refid="box2">panel 2</ce:cross-ref>
                     <ce:float-anchor refid="box2"/>).</ce:para>
                  <ce:para id="para450" view="all">It is our view that domestic NCD financing efforts should start by enhancing public finance capability through general taxation or social health insurance, coupled with fiscal reforms.<ce:cross-ref id="cecref810" refid="bib32">
                        <ce:sup loc="post">32</ce:sup>
                     </ce:cross-ref> Complementary appro-aches, such as results-based financing, debt buy-backs and swaps, and public–private partnerships, have shown promise for mobilising private capital and merit further study for specific NCD issues, but their application could be limited by an absence of a robust private sector, especially in LICs.<ce:cross-refs id="cecrefs110" refid="bib33 bib34">
                        <ce:sup loc="post">33,34</ce:sup>
                     </ce:cross-refs> We stress the importance of removing harmful or ineffective subsidies, such as those on fossil fuels and some agricultural commodities (eg, sugar, and intensive livestock production), in some countries; these actions could generate substantial fiscal space, leading to more resources for health.<ce:cross-refs id="cecrefs120" refid="bib4 bib35">
                        <ce:sup loc="post">4,35</ce:sup>
                     </ce:cross-refs>
                  </ce:para>
                  <ce:para id="para460" view="all">National governments should also be made aware that public finance of NCD interventions reduces household out-of-pocket spending and can provide considerable protection against medical impoverishment,<ce:cross-refs id="cecrefs130" refid="bib36 bib37">
                        <ce:sup loc="post">36,37</ce:sup>
                     </ce:cross-refs> extending the benefits of NCD investments beyond SDG target 3.4 to SDG target 3.8 (achieving UHC) and SDG target 1 (poverty reduction). Finally, ministries of health urgently need to implement robust and transparent priority-setting and health technology assessment mechanisms to limit the use of low value-for-money NCD technologies, including in the private sector.<ce:cross-refs id="cecrefs140" refid="bib38 bib39">
                        <ce:sup loc="post">38,39</ce:sup>
                     </ce:cross-refs> Rationalising NCD spending and aligning national health benefits packages with the model list (<ce:cross-ref id="cecref820" refid="tbl1">table 1</ce:cross-ref>) could promote stewardship and respond to increasing pressure from commercial interests.<ce:cross-ref id="cecref830" refid="bib40">
                        <ce:sup loc="post">40</ce:sup>
                     </ce:cross-ref> Our recommendations could bring focus to national NCD strategies by guiding scarce resources towards high-value care that benefits the greatest number of patients. In 2020, the Ministry of Health in Ethiopia revised their health benefits package to consider a wide range of NCD interventions,<ce:cross-ref id="cecref840" refid="bib41">
                        <ce:sup loc="post">41</ce:sup>
                     </ce:cross-ref> underscoring the importance of priority-setting institutions and mechanisms in shaping the national NCD agenda (<ce:cross-ref id="cecref850" refid="box3">panel 3</ce:cross-ref>
                     <ce:float-anchor refid="box3"/>).</ce:para>
               </ce:section>
               <ce:section id="cesec80" view="all">
                  <ce:section-title id="cestitle90">The role of development partners and international finance</ce:section-title>
                  <ce:para id="para470" view="all">Our report has important implications for international agencies, bilaterals, and civil society organisations. National governments bear primary responsibility for financing NCD care, and in general, development aid needs to shift from directly financing health care—in all but the poorest countries—to financing global public goods and supporting collective action.<ce:cross-refs id="cecrefs150" refid="bib4 bib24">
                        <ce:sup loc="post">4,24</ce:sup>
                     </ce:cross-refs> Less than 2% of development assistance for health is devoted to NCDs;<ce:cross-ref id="cecref860" refid="bib48">
                        <ce:sup loc="post">48</ce:sup>
                     </ce:cross-ref> this share has remained stagnant over the past decade and is not proportionate to need or disease burden, even in the poorest countries.<ce:cross-ref id="cecref870" refid="bib18">
                        <ce:sup loc="post">18</ce:sup>
                     </ce:cross-ref> Our findings could inform emerging collective finance efforts, such as the Multi-Partner Trust Fund for NCDs,<ce:cross-ref id="cecref880" refid="bib49">
                        <ce:sup loc="post">49</ce:sup>
                     </ce:cross-ref> and provide guidance for donors looking for catalytic investment opportunities. Development partners working in countries that are struggling to finance a basic NCD package should strongly consider primary health-care investments that have spill-over benefits for NCD care and protect hard-won gains in priority populations, such as people living with HIV and tuberculosis.<ce:cross-refs id="cecrefs160" refid="bib50 bib51">
                        <ce:sup loc="post">50,51</ce:sup>
                     </ce:cross-refs> Other bilaterals could follow the Norwegian government's example by developing NCD strategies.<ce:cross-ref id="cecref890" refid="bib52">
                        <ce:sup loc="post">52</ce:sup>
                     </ce:cross-ref>
                  </ce:para>
                  <ce:para id="para480" view="all">Advocacy for NCD financing and collective action should not be framed as another global health initiative. The COVID-19 pandemic has shown that siloed programmes are increasingly unfit for purpose and need to be integrated within primary health care.<ce:cross-refs id="cecrefs170" refid="bib4 bib7">
                        <ce:sup loc="post">4,7</ce:sup>
                     </ce:cross-refs> The growing burden of multimorbidity and the bidirectional relationships between communicable diseases and NCDs underscore the need to dismantle disease-specific silos, emphasising reforms and investments that improve a wide range of health outcomes. Additionally, missed opportunities to prevent NCDs have arguably increased population susceptibility to COVID-19-related mortality, a pattern that could repeat itself in future pandemics.<ce:cross-ref id="cecref900" refid="bib53">
                        <ce:sup loc="post">53</ce:sup>
                     </ce:cross-ref> Pandemic preparedness and global health security cannot be separated from efforts to prevent NCDs and strengthen basic services for chronic care and acute complications.<ce:cross-ref id="cecref910" refid="bib54">
                        <ce:sup loc="post">54</ce:sup>
                     </ce:cross-ref>
                  </ce:para>
                  <ce:para id="para490" view="all">Our assessment of costs and benefits aligns with previous country-specific NCD investment cases that have shown high returns.<ce:cross-refs id="cecrefs180" refid="bib55 bib56">
                        <ce:sup loc="post">55,56</ce:sup>
                     </ce:cross-refs> Policy makers can be assured that these NCD interventions represent a good use of money, on par with many interventions for the unfinished agenda of communicable, maternal, perinatal, and nutritional conditions.<ce:cross-refs id="cecrefs190" refid="bib24 bib57">
                        <ce:sup loc="post">24,57</ce:sup>
                     </ce:cross-refs> Many governments face international and local pressure to deliver on the unfinished agenda. We do not advocate for diversion of resources from successful, cost-effective programmes. Instead, we propose that any increases in health spending carefully balance the urgent need to close gaps in maternal and child health and communicable disease outcomes with the need to enhance capacity to prevent and treat NCDs, which are now responsible for comparable loss of health and other emerging health issues. Rapid epidemiological and demographic transitions in LICs and lower-middle-income countries mean that there is a substantial opportunity cost to not building capacity for NCDs: many of these countries already have the highest NCD mortality rates in the world, and their situation, and thus global inequalities, will worsen without pre-emptive action.<ce:cross-refs id="cecrefs200" refid="bib4 bib58">
                        <ce:sup loc="post">4,58</ce:sup>
                     </ce:cross-refs>
                  </ce:para>
               </ce:section>
               <ce:section id="cesec90" view="all">
                  <ce:section-title id="cestitle100">Non-financial implementation considerations</ce:section-title>
                  <ce:para id="para500" view="all">Adequate funding is necessary but not sufficient to deliver on SDG target 3.4; non-financial barriers also need to be addressed. To date, the six intersectoral policy interventions in the package have been in-sufficiently implemented worldwide, including in LMICs.<ce:cross-ref id="cecref920" refid="bib59">
                        <ce:sup loc="post">59</ce:sup>
                     </ce:cross-ref> These policies require considerable political will, a shift towards a whole-of-government approach to health,<ce:cross-ref id="cecref930" refid="bib60">
                        <ce:sup loc="post">60</ce:sup>
                     </ce:cross-ref> and strong civil society support.<ce:cross-ref id="cecref940" refid="bib61">
                        <ce:sup loc="post">61</ce:sup>
                     </ce:cross-ref> Tobacco taxes are particularly effective, but in many countries, tax rates have not kept up with income growth, so the affordability of cigarettes has either stayed the same or increased over time.<ce:cross-ref id="cecref950" refid="bib62">
                        <ce:sup loc="post">62</ce:sup>
                     </ce:cross-ref> Top priorities for international collective action<ce:cross-ref id="cecref960" refid="bib4">
                        <ce:sup loc="post">4</ce:sup>
                     </ce:cross-ref> in the coming decade include better monitoring of the effectiveness of health taxes using scorecards that factor in affordability, tax structure, and other considerations beyond prices,<ce:cross-ref id="cecref970" refid="bib63">
                        <ce:sup loc="post">63</ce:sup>
                     </ce:cross-ref> and support for regional harmonisation of fiscal and regulatory policies to reduce smuggling between countries with porous borders.<ce:cross-ref id="cecref980" refid="bib64">
                        <ce:sup loc="post">64</ce:sup>
                     </ce:cross-ref>
                  </ce:para>
                  <ce:para id="para510" view="all">Taxes and regulations on unhealthy products are usually met with strong and influential opposition from the industries concerned, so another priority for collective action in the coming years will be supporting LMICs to help counter industry efforts and reduce resistance. In some cases, health advocates will need to call for roll-back of policies that are too accommodative to industry and less effective, such as voluntary (rather than mandatory) food regulations.<ce:cross-ref id="cecref990" refid="bib65">
                        <ce:sup loc="post">65</ce:sup>
                     </ce:cross-ref> The stakes are high: fully implementing these six intersectoral policies, without even scaling up any clinical interventions, could achieve a 24% reduction in the probability of death from NCD4 between ages 30 and 70 years worldwide, accounting for about two-thirds of the health gains in the reference scenario (<ce:cross-ref id="cecref1000" refid="sec1">appendix p 43</ce:cross-ref>). However, if these policies were not implemented, an additional US$38 billion annually would need to be spent on clinical interventions to achieve similar mortality reductions (<ce:cross-ref id="cecref1010" refid="sec1">appendix p 44</ce:cross-ref>)—triple the costs we estimated in the reference scenario.</ce:para>
                  <ce:para id="para520" view="all">Cost-effectiveness is not the only criterion by which countries can set priorities to achieve SDG target 3.4. Most of the interventions we analysed require a skilled health workforce that can deliver longitudinal care and has access to adequate supplies of medications and diagnostics. <ce:cross-ref id="cecref1020" refid="tbl4">Table 4</ce:cross-ref>
                     <ce:float-anchor refid="tbl4"/> presents several characteristics (<ce:cross-ref id="cecref1030" refid="sec1">appendix pp 13–15</ce:cross-ref>) related to implementation feasibility in very resource-limited settings. The potential for substantial human resource bottlenecks (eg, long training times for oncologists and cardiologists) might temper local enthusiasm for some interventions in settings where preservice training programmes are relatively less developed or have been disrupted by the pandemic. In addition, although we presume public finance of the intervention package, most countries will require some component of private sector provision. Contracting with private sector providers to implement priority interventions has notable strengths and pitfalls.<ce:cross-ref id="cecref1040" refid="bib4">
                        <ce:sup loc="post">4</ce:sup>
                     </ce:cross-ref>
                  </ce:para>
                  <ce:para id="para530" view="all">The rate at which clinical interventions can be scaled is a key factor in determining achievement of SDG target 3.4. Scale-up will require new case-finding efforts, especially for conditions that are largely asymptomatic and often go undiagnosed, and complementary measures to ensure high-quality care.<ce:cross-ref id="cecref1050" refid="bib66">
                        <ce:sup loc="post">66</ce:sup>
                     </ce:cross-ref> Organised screening activities need to be implemented for cervical cancer and cardiovascular disease primary prevention; these can be readily integrated into general primary health care and into communicable diseases programmes in some cases (eg, HIV/AIDS).<ce:cross-ref id="cecref1060" refid="bib51">
                        <ce:sup loc="post">51</ce:sup>
                     </ce:cross-ref> In addition, operation and implementation research perspectives are urgently needed to design, refine, and scale approaches to delivering care, especially in hard-to-reach populations.<ce:cross-refs id="cecrefs210" refid="bib67 bib68">
                        <ce:sup loc="post">67,68</ce:sup>
                     </ce:cross-refs> To expand access to NCD care, including specialised providers, health ministries should consider developing telehealth policies and strategies that align with their locally tailored package.<ce:cross-ref id="cecref1070" refid="bib69">
                        <ce:sup loc="post">69</ce:sup>
                     </ce:cross-ref>
                  </ce:para>
                  <ce:para id="para540" view="all">Even when cost-effective primary health-care inter-ventions are an option, as is the case for cardiovascular disease, interventions at referral and specialised hospitals warrant consideration within national NCD strategies.<ce:cross-ref id="cecref1080" refid="bib18">
                        <ce:sup loc="post">18</ce:sup>
                     </ce:cross-ref> For example, administration of multimodal cancer therapies is best done at referral centres, which can provide support for early detection and primary treatment efforts at first-level hospitals.<ce:cross-ref id="cecref1090" refid="bib70">
                        <ce:sup loc="post">70</ce:sup>
                     </ce:cross-ref> Referral hospitals also serve as teaching centres that can oversee preservice and in-service training of the primary health-care workforce on NCD management and help provide quality assurance.<ce:cross-ref id="cecref1100" refid="bib71">
                        <ce:sup loc="post">71</ce:sup>
                     </ce:cross-ref>
                  </ce:para>
               </ce:section>
               <ce:section id="cesec100" view="all">
                  <ce:section-title id="cestitle110">Limitations and caveats</ce:section-title>
                  <ce:para id="para550" view="all">The analyses we undertook in this report have several important limitations and caveats (<ce:cross-ref id="cecref1110" refid="sec1">appendix pp 34–35</ce:cross-ref>). There is a great deal of uncertainty regarding mortality trends since 2019 that we attempt to address through scenario analyses. Intervention-specific parameters are derived from the best available evidence, but data in LMICs are scarce, especially on intervention costs and coverage levels. Our modelling assumes the COVID-19 pandemic will be under control in most countries by 2023, but faltering roll-out of COVID-19 vaccines and emergence of new variants might extend this timeline and further constrain action on NCDs. Our report focuses on one NCD outcome, premature mortality. Health systems have many objectives, including reductions in non-fatal diseases and improvements in non-health outcomes, such as pain and distress, and financial protection. Finally, the recommendations in this report are intended to be generic guidance, not a prescription. We merely provide a framework, acknowledging that local cultural, political, and economic factors will greatly influence the application of our work in particular countries.</ce:para>
               </ce:section>
               <ce:section id="cesec110" view="all">
                  <ce:section-title id="cestitle120">Conclusion</ce:section-title>
                  <ce:para id="para560" view="all">This Health Policy lays out an ambitious but pragmatic approach to helping LMICs get back on track towards achieving SDG target 3.4 in the wake of the COVID-19 pandemic. Focusing on a relatively small number of highly cost-effective NCD interventions to scale up fits with the progressive universalist approach to UHC.<ce:cross-refs id="cecrefs220" refid="bib24 bib72">
                        <ce:sup loc="post">24,72</ce:sup>
                     </ce:cross-refs> The interventions featured in this report cover a range of diseases, risk factors, and delivery platforms and build a foundation for future expansion of NCD services within integrated UHC systems.</ce:para>
                  <ce:para id="para570" view="all">Our report has implications for NCD target-setting beyond 2030. Unlike communicable, maternal, perinatal, and nutritional conditions, NCDs are less well suited to short-term targets, especially on mortality. Some countries that invest in these interventions might fail to achieve SDG target 3.4, but these investments could contribute to long-term sustained reductions in NCDs. We propose that discourse about NCD targets should be reoriented for the long term, particularly in the leadup to the UN High-Level Meeting on NCDs in 2025. Future global goals, if they are to be developed at all, should bear in mind the marked heterogeneity in NCD epidemiology and health system capacity across countries. Targets should be set to be achievable in the poorest countries and include both outcome and process targets and indicators, emphasising interventions that make health systems more resilient, nimble, equitable, and responsive to accelerating demographic and epidemiological transitions. Further, since population ageing will only accelerate in the next decades, post-2030 targets will increasingly need to monitor NCD outcomes among individuals over age 70 years.<ce:cross-ref id="cecref1120" refid="bib73">
                        <ce:sup loc="post">73</ce:sup>
                     </ce:cross-ref>
                  </ce:para>
                  <ce:para id="para580" view="all">We conclude that achieving SDG target 3.4 is realistic in many countries, although some LICs and lower-middle-income countries might require considerable financial and technical support from the international community. Additionally, new delivery approaches are urgently needed to support rapid scale-up of these interventions. Although SDG target 3.4 calls for substantial reductions in NCD mortality, the reality is that the future of global health is a future dominated by NCDs. By investing now, countries can alter this epidemiological trajectory to enhance the health of working-age adults and save scarce public resources, especially by implementing inter-sectoral policies to reduce tobacco, alcohol, and sodium intake. The discourse around NCD priorities must shift away from quick wins and siloed thinking: the NCD agenda is an integral part of sustainable development.<ce:cross-ref id="cecref1130" refid="bib74">
                        <ce:sup loc="post">74</ce:sup>
                     </ce:cross-ref> Fundamentally, investments in NCD prevention and care are investments in the health systems of tomorrow, and they can yield high returns during the SDG period and beyond, provided they are made wisely.</ce:para>
                  <ce:section id="cesec120" view="all">
                     <ce:section-title id="cestitle130">NCD Countdown 2030 collaborators</ce:section-title>
                     <ce:para id="para590" role="acknowledgement" view="all">David A Watkins (MD; Division of General Internal Medicine, Department of Medicine, and Department of Global Health, University of Washington, Seattle, WA, USA), William T Msemburi* (PhD; Division of Data, Analytics, and Delivery for Impact, WHO, Geneva, Switzerland), Sarah J Pickersgill* (MPH; Department of Global Health, University of Washington, Seattle, WA, USA), Yoshito Kawakatsu (MPH; Department of Global Health, University of Washington, Seattle, WA, USA), Adrian Gheorghe (PhD; School of Public Health, Imperial College London, London, UK), Katie Dain (MSc; NCD Alliance, London, UK), Kjell Arne Johansson (PhD; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway; Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway), Sanaa Said (MD; School of Health and Medical Sciences, State University of Zanzibar, Zanzibar, Tanzania), Nina Renshaw (MA; NCD Alliance, Geneva, Switzerland), Mieraf T Tolla (PhD; Addis Centre for Ethics and Priority Setting, Addis Ababa University, Addis Ababa, Ethiopia), Pakwanja D Twea (MSc; Department of Planning and Policy Development, Ministry of Health, Lilongwe, Malawi), Cherian Varghese (MD; Department of Noncommunicable diseases, World Health Organization, Geneva, Switzerland), Prof Kalipso Chalkidou (PhD; School of Public Health, Imperial College London, London, UK), Prof Majid Ezzati (FMedSci; School of Public Health, Imperial College London, London, UK; Regional Institute for Population Studies, University of Ghana, Legon, Ghana), Prof Ole F Norheim (PhD; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway; Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA). *Contributed equally.</ce:para>
                     <ce:para id="para600" role="acknowledgement" view="all">
                        <ce:bold>Contributors</ce:bold>
                     </ce:para>
                     <ce:para id="para610" role="acknowledgement" view="all">DAW designed the study with input from OFN, KC, and ME. WTM, SJP, YK, and AG collected and analysed the data and developed the tables, figures, and appendix. All authors interpreted the data. DAW drafted the manuscript. All authors revised the draft manuscript critically for important intellectual content. The views expressed in this report are solely the responsibility of the authors and they do not necessarily reflect the views, decisions, or policies of the institutions with which they are affiliated.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:para id="para620" view="all">
                  <ce:display>
                     <ce:textbox id="cetextbox10">
                        <ce:textbox-body>
                           <ce:sections>
                              <ce:para id="para630" view="all">Correspondence to: Dr David Watkins, Department of Global Health, Hans Rosling Center for Population Health, University of Washington, Seattle, WA 98195, USA <ce:inter-ref id="interrefs10" xlink:href="mailto:davidaw@uw.edu" xlink:type="simple">davidaw@uw.edu</ce:inter-ref>
                              </ce:para>
                           </ce:sections>
                        </ce:textbox-body>
                     </ce:textbox>
                  </ce:display>
               </ce:para>
            </ce:sections>
            <ce:conflict-of-interest id="conflict-of-interest" view="all">
               <ce:section-title id="cestitle140">Declaration of interests</ce:section-title>
               <ce:para id="para640" view="all">DAW, WTM, SJP, and OFN report funding from the Trond Mohn Foundation (Bergen Centre for Ethics and Priority Setting grant) for this work. DAW reports funding from Vital Strategies and from the World Bank Group for related work. ME reports funding from the AstraZeneca Young Health Programme for related work. OFN reports funding from the Norwegian Agency for Development Cooperation for related work. All other authors declare no competing interests.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ceack10" view="all">
               <ce:para id="para650" view="all">
                  <ce:bold>Acknowledgments</ce:bold>
               </ce:para>
               <ce:para id="para660" role="acknowledgement" view="all">The authors wish to thank James Bennett for contributing epidemiological data used in this Health Policy and Robert Beaglehole for providing important comments on an earlier draft of the manuscript. This Health Policy was supported by the Trond Mohn Foundation, the Norwegian Agency for Development Cooperation, the University of Bergen through the Bergen Centre for Ethics and Priority Setting (project number 813596), and the UK Research and Innovation's Medical Research Council (grant number MR/V034057/1). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility to submit for publication.</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="sec1" view="extended">
                  <ce:section-title id="cestitle150">Supplementary Material</ce:section-title>
                  <ce:para id="para670" view="all">
                     <ce:display>
                        <ce:e-component id="ecomp10">
                           <ce:label>Supplementary appendix</ce:label>
                           <ce:link locator="mmc1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:href="pii:S0140673621023473/mmc1"/>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="bibl10" view="all">
               <ce:section-title id="cestitle160">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec10" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>1</ce:label>
                     <sb:reference id="sbref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>UN Sustainable Development Goals</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Goal 3: ensure healthy lives and promote well-being for all at all ages</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="interrefs20" xlink:href="http://www.un.org/sustainabledevelopment/health/" xlink:type="simple">http://www.un.org/sustainabledevelopment/health/</ce:inter-ref>
                              <sb:date>2016</sb:date>
                              <sb:date-accessed day="26" month="8" year="2020"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext10">UN Sustainable Development Goals. Goal 3: ensure healthy lives and promote well-being for all at all ages. 2016. http://www.un.org/sustainabledevelopment/health/ (accessed Aug 26, 2020).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>2</ce:label>
                     <sb:reference id="sbref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Ezzati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z</ce:given-name>
                                 <ce:surname>Obermeyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I</ce:given-name>
                                 <ce:surname>Tzoulaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>BM</ce:given-name>
                                 <ce:surname>Mayosi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Elliott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>DA</ce:given-name>
                                 <ce:surname>Leon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Contributions of risk factors and medical care to cardiovascular mortality trends</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat Rev Cardiol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>508</sb:first-page>
                              <sb:last-page>530</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext20">Ezzati M, Obermeyer Z, Tzoulaki I, Mayosi BM, Elliott P, Leon DA. Contributions of risk factors and medical care to cardiovascular mortality trends. Nat Rev Cardiol 2015; 12: 508–30.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>3</ce:label>
                     <sb:reference id="sbref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Ezzati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E</ce:given-name>
                                 <ce:surname>Riboli</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Can noncommunicable diseases be prevented? Lessons from studies of populations and individuals</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>337</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1482</sb:first-page>
                              <sb:last-page>1487</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext30">Ezzati M, Riboli E. Can noncommunicable diseases be prevented? Lessons from studies of populations and individuals. Science 2012; 337: 1482–87.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>4</ce:label>
                     <sb:reference id="sbref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>DA</ce:given-name>
                                 <ce:surname>Watkins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G</ce:given-name>
                                 <ce:surname>Yamey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Schäferhoff</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Alma-Ata at 40 years: reflections from the <ce:italic>Lancet</ce:italic> Commission on Investing in Health</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>392</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1434</sb:first-page>
                              <sb:last-page>1460</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext40">Watkins DA, Yamey G, Schäferhoff M, et al. Alma-Ata at 40 years: reflections from the Lancet Commission on Investing in Health. Lancet 2018; 392: 1434–60.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>5</ce:label>
                     <sb:reference id="sbref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>NCD Countdown 2030 collaborators</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>392</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1072</sb:first-page>
                              <sb:last-page>1088</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext50">NCD Countdown 2030 collaborators. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet 2018; 392: 1072–88.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>6</ce:label>
                     <sb:reference id="sbref60">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>NCD Countdown 2030 collaborators</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>NCD Countdown 2030: pathways to achieving Sustainable Development Goal target 3.4</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>396</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>918</sb:first-page>
                              <sb:last-page>934</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext60">NCD Countdown 2030 collaborators. NCD Countdown 2030: pathways to achieving Sustainable Development Goal target 3.4. Lancet 2020; 396: 918–34.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>7</ce:label>
                     <sb:reference id="sbref70">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>WHO</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Rapid assessment of service delivery for NCDs during the COVID-19 pandemic</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2020</sb:date>
                              <sb:publisher>
                                 <sb:name>World Health Organization</sb:name>
                                 <sb:location>Geneva</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext70">WHO. Rapid assessment of service delivery for NCDs during the COVID-19 pandemic. Geneva: World Health Organization, 2020.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>8</ce:label>
                     <sb:reference id="sbref80">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>SL</ce:given-name>
                                 <ce:surname>Harrison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>BJR</ce:given-name>
                                 <ce:surname>Buckley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>JM</ce:given-name>
                                 <ce:surname>Rivera-Caravaca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>GYH</ce:given-name>
                                 <ce:surname>Lip</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur Heart J Qual Care Clin Outcomes</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>330</sb:first-page>
                              <sb:last-page>339</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext80">Harrison SL, Buckley BJR, Rivera-Caravaca JM, Zhang J, Lip GYH. Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews. Eur Heart J Qual Care Clin Outcomes 2021; 7: 330–39.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>9</ce:label>
                     <sb:reference id="sbref90">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Chai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Biol Med</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>298</sb:first-page>
                              <sb:last-page>307</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext90">Yang L, Chai P, Yu J, Fan X. Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants. Cancer Biol Med 2021; 18: 298–307.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>10</ce:label>
                     <sb:reference id="sbref100">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>FV</ce:given-name>
                                 <ce:surname>Gerayeli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Milne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C</ce:given-name>
                                 <ce:surname>Cheung</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>COPD and the risk of poor outcomes in COVID-19: a systematic review and meta-analysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>EClinicalMedicine</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:article-number>100789</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext100">Gerayeli FV, Milne S, Cheung C, et al. COPD and the risk of poor outcomes in COVID-19: a systematic review and meta-analysis. EClinicalMedicine 2021; 33: 100789.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>11</ce:label>
                     <sb:reference id="sbref110">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V</ce:given-name>
                                 <ce:surname>Kontis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>JE</ce:given-name>
                                 <ce:surname>Bennett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>RM</ce:given-name>
                                 <ce:surname>Parks</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Lessons learned and lessons missed: impact of the coronavirus disease 2019 (COVID-19) pandemic on all-cause mortality in 40 industrialised countries and US states prior to mass vaccination</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Wellcome Open Res</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2022</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>279</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext110">Kontis V, Bennett JE, Parks RM, et al. Lessons learned and lessons missed: impact of the coronavirus disease 2019 (COVID-19) pandemic on all-cause mortality in 40 industrialised countries and US states prior to mass vaccination. Wellcome Open Res 2022; 6: 279.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>12</ce:label>
                     <sb:reference id="sbref120">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>World Bank</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>World development report 1993: investing in health</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>1993</sb:date>
                              <sb:publisher>
                                 <sb:name>Oxford University Press</sb:name>
                                 <sb:location>New York</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext120">World Bank. World development report 1993: investing in health. New York: Oxford University Press, 1993.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>13</ce:label>
                     <sb:reference id="sbref130">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R</ce:given-name>
                                 <ce:surname>Laxminarayan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>AJ</ce:given-name>
                                 <ce:surname>Mills</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>JG</ce:given-name>
                                 <ce:surname>Breman</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Advancement of global health: key messages from the Disease Control Priorities Project</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>367</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1193</sb:first-page>
                              <sb:last-page>1208</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext130">Laxminarayan R, Mills AJ, Breman JG, et al. Advancement of global health: key messages from the Disease Control Priorities Project. Lancet 2006; 367: 1193–208.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>14</ce:label>
                     <sb:reference id="sbref140">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>DT</ce:given-name>
                                 <ce:surname>Jamison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A</ce:given-name>
                                 <ce:surname>Alwan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>CN</ce:given-name>
                                 <ce:surname>Mock</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Universal health coverage and intersectoral action for health: key messages from Disease Control Priorities, 3rd edition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>391</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1108</sb:first-page>
                              <sb:last-page>1120</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext140">Jamison DT, Alwan A, Mock CN, et al. Universal health coverage and intersectoral action for health: key messages from Disease Control Priorities, 3rd edition. Lancet 2018; 391: 1108–20.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>15</ce:label>
                     <sb:reference id="sbref150">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H</ce:given-name>
                                 <ce:surname>Gelband</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R</ce:given-name>
                                 <ce:surname>Sankaranarayanan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>CL</ce:given-name>
                                 <ce:surname>Gauvreau</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from Disease Control Priorities, 3rd edition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>387</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2133</sb:first-page>
                              <sb:last-page>2144</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext150">Gelband H, Sankaranarayanan R, Gauvreau CL, et al. Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from Disease Control Priorities, 3rd edition. Lancet 2016; 387: 2133–44.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>16</ce:label>
                     <sb:reference id="sbref160">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Prabhakaran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Anand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Watkins</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>3rd edn</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>391</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1224</sb:first-page>
                              <sb:last-page>1236</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext160">Prabhakaran D, Anand S, Watkins D, et al. Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edn. Lancet, 2018; 391: 1224–36.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>17</ce:label>
                     <sb:reference id="sbref170">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>WHO</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Technical annex: updated appendix 3 of the WHO Global NCD Action Plan 2013–2020</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="interrefs30" xlink:href="https://www.who.int/ncds/governance/technical_annex.pdf?ua=1" xlink:type="simple">https://www.who.int/ncds/governance/technical_annex.pdf?ua=1</ce:inter-ref>
                              <sb:date>April 12, 2017</sb:date>
                              <sb:date-accessed day="14" month="6" year="2020"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext170">WHO. Technical annex: updated appendix 3 of the WHO Global NCD Action Plan 2013–2020. April 12, 2017. https://www.who.int/ncds/governance/technical_annex.pdf?ua=1 (accessed June 14, 2020).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>18</ce:label>
                     <sb:reference id="sbref180">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G</ce:given-name>
                                 <ce:surname>Bukhman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>AO</ce:given-name>
                                 <ce:surname>Mocumbi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R</ce:given-name>
                                 <ce:surname>Atun</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The Lancet NCDI Poverty Commission: bridging a gap in universal health coverage for the poorest billion</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>396</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>991</sb:first-page>
                              <sb:last-page>1044</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext180">Bukhman G, Mocumbi AO, Atun R, et al. The Lancet NCDI Poverty Commission: bridging a gap in universal health coverage for the poorest billion. Lancet 2020; 396: 991–1044.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>19</ce:label>
                     <sb:reference id="sbref190">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>WHO</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Global health estimates: life expectancy and leading causes of death and disability</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2020</sb:date>
                              <sb:publisher>
                                 <sb:name>World Health Organization</sb:name>
                                 <sb:location>Geneva</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext190">WHO. Global health estimates: life expectancy and leading causes of death and disability. Geneva: World Health Organization, 2020.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>20</ce:label>
                     <sb:reference id="sbref200">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V</ce:given-name>
                                 <ce:surname>Kontis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>CD</ce:given-name>
                                 <ce:surname>Mathers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Rehm</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Contribution of six risk factors to achieving the 25 × 25 non-communicable disease mortality reduction target: a modelling study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>384</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>427</sb:first-page>
                              <sb:last-page>437</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext200">Kontis V, Mathers CD, Rehm J, et al. Contribution of six risk factors to achieving the 25 × 25 non-communicable disease mortality reduction target: a modelling study. Lancet 2014; 384: 427–37.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>21</ce:label>
                     <sb:reference id="sbref210">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Watkins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Hale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B</ce:given-name>
                                 <ce:surname>Hutchinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I</ce:given-name>
                                 <ce:surname>Kataria</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V</ce:given-name>
                                 <ce:surname>Kontis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R</ce:given-name>
                                 <ce:surname>Nugent</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Investing in non-communicable disease risk factor control among adolescents worldwide: a modelling study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>BMJ Glob Health</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:article-number>e001335</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext210">Watkins D, Hale J, Hutchinson B, Kataria I, Kontis V, Nugent R. Investing in non-communicable disease risk factor control among adolescents worldwide: a modelling study. BMJ Glob Health 2019; 4: e001335.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>22</ce:label>
                     <sb:reference id="sbref220">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>DA</ce:given-name>
                                 <ce:surname>Watkins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y</ce:given-name>
                                 <ce:surname>Kawakatsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>SJ</ce:given-name>
                                 <ce:surname>Pickersgill</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>SE</ce:given-name>
                                 <ce:surname>Horton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>DT</ce:given-name>
                                 <ce:surname>Jamison</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Resource requirements for essential universal health coverage: a modelling study based on findings from Disease Control Priorities, 3rd edition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet Glob Health</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e829</sb:first-page>
                              <sb:last-page>e839</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext220">Watkins DA, Qi J, Kawakatsu Y, Pickersgill SJ, Horton SE, Jamison DT. Resource requirements for essential universal health coverage: a modelling study based on findings from Disease Control Priorities, 3rd edition. Lancet Glob Health 2020; 8: e829–39.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>23</ce:label>
                     <sb:reference id="sbref230">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>AY</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Horton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>DT</ce:given-name>
                                 <ce:surname>Jamison</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Benefit-cost analysis in disease control priorities</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:edited-book>
                              <sb:editors>
                                 <sb:editor>
                                    <ce:given-name>DT</ce:given-name>
                                    <ce:surname>Jamison</ce:surname>
                                 </sb:editor>
                                 <sb:editor>
                                    <ce:given-name>H</ce:given-name>
                                    <ce:surname>Gelband</ce:surname>
                                 </sb:editor>
                                 <sb:editor>
                                    <ce:given-name>S</ce:given-name>
                                    <ce:surname>Horton</ce:surname>
                                 </sb:editor>
                                 <sb:et-al/>
                              </sb:editors>
                              <sb:title>
                                 <sb:maintitle>Disease control priorities: improving health and reducing poverty</sb:maintitle>
                              </sb:title>
                              <sb:edition>3rd edn.</sb:edition>
                              <sb:book-series>
                                 <sb:series>
                                    <sb:volume-nr>vol 9</sb:volume-nr>
                                 </sb:series>
                              </sb:book-series>
                              <sb:date>2017</sb:date>
                              <sb:publisher>
                                 <sb:name>The International Bank for Reconstruction and Development and The World Bank</sb:name>
                                 <sb:location>Washington, DC</sb:location>
                              </sb:publisher>
                           </sb:edited-book>
                           <sb:pages>
                              <sb:first-page>167</sb:first-page>
                              <sb:last-page>181</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:comment>3rd edn.</sb:comment>
                     </sb:reference>
                     <ce:source-text id="sourcetext230">Chang AY, Horton S, Jamison DT. Benefit-cost analysis in disease control priorities, 3rd edn. In: Jamison DT, Gelband H, Horton S, et al, eds. Disease control priorities: improving health and reducing poverty, vol 9, 3rd edn. Washington, DC; The International Bank for Reconstruction and Development and The World Bank, 2017: 167–181.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>24</ce:label>
                     <sb:reference id="sbref240">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>DT</ce:given-name>
                                 <ce:surname>Jamison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>LH</ce:given-name>
                                 <ce:surname>Summers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G</ce:given-name>
                                 <ce:surname>Alleyne</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Global health 2035: a world converging within a generation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>382</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1898</sb:first-page>
                              <sb:last-page>1955</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext240">Jamison DT, Summers LH, Alleyne G, et al. Global health 2035: a world converging within a generation. Lancet 2013; 382: 1898–955.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>25</ce:label>
                     <sb:reference id="sbref250">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Ochalek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Lomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K</ce:given-name>
                                 <ce:surname>Claxton</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2015</sb:date>
                              <sb:publisher>
                                 <sb:name>Centre for Health Economics, University of York</sb:name>
                                 <sb:location>York</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext250">Ochalek J, Lomas J, Claxton K. Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data. York: Centre for Health Economics, University of York, 2015.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>26</ce:label>
                     <sb:reference id="sbref260">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>JCN</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>LL</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>NJ</ce:given-name>
                                 <ce:surname>Wareham</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The <ce:italic>Lancet</ce:italic> Commission on diabetes: using data to transform diabetes care and patient lives</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>396</sb:volume-nr>
                              </sb:series>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2019</sb:first-page>
                              <sb:last-page>2082</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext260">Chan JCN, Lim LL, Wareham NJ, et al. The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet 2021; 396: 2019–82.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>27</ce:label>
                     <sb:reference id="sbref270">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>LA</ce:given-name>
                                 <ce:surname>Robinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>JK</ce:given-name>
                                 <ce:surname>Hammitt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Cecchini</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Reference case guidelines for benefit-cost analysis in global health and development</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2019</sb:date>
                              <sb:publisher>
                                 <sb:name>Harvard T.H. Chan School of Public Health</sb:name>
                                 <sb:location>Boston, MA</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext270">Robinson LA, Hammitt JK, Cecchini M, et al. Reference case guidelines for benefit-cost analysis in global health and development. Boston, MA: Harvard T.H. Chan School of Public Health, 2019.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>28</ce:label>
                     <sb:reference id="sbref280">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K</ce:given-name>
                                 <ce:surname>Stenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O</ce:given-name>
                                 <ce:surname>Hanssen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>TT</ce:given-name>
                                 <ce:surname>Edejer</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Financing transformative health systems towards achievement of the health Sustainable Development Goals: a model for projected resource needs in 67 low-income and middle-income countries</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet Glob Health</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e875</sb:first-page>
                              <sb:last-page>e887</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext280">Stenberg K, Hanssen O, Edejer TT, et al. Financing transformative health systems towards achievement of the health Sustainable Development Goals: a model for projected resource needs in 67 low-income and middle-income countries. Lancet Glob Health 2017; 5: e875–87.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>29</ce:label>
                     <sb:reference id="sbref290">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>DA</ce:given-name>
                                 <ce:surname>Watkins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H</ce:given-name>
                                 <ce:surname>Saxenian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>SE</ce:given-name>
                                 <ce:surname>Horton</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Costing universal health coverage: an update of the DCP3 costing model for the <ce:italic>Lancet</ce:italic> Commission on Investing in Health</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="interrefs40" xlink:href="http://dcp-3.org/resources/costing-universal-health-coverage-update-dcp3-costing-model-lancet-commission-investing" xlink:type="simple">http://dcp-3.org/resources/costing-universal-health-coverage-update-dcp3-costing-model-lancet-commission-investing</ce:inter-ref>
                              <sb:date>Oct 18, 2018</sb:date>
                              <sb:date-accessed day="26" month="8" year="2020"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext290">Watkins DA, Qi J, Saxenian H, Horton SE. Costing universal health coverage: an update of the DCP3 costing model for the Lancet Commission on Investing in Health. Oct 18, 2018. http://dcp-3.org/resources/costing-universal-health-coverage-update-dcp3-costing-model-lancet-commission-investing (accessed Aug 26, 2020).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>30</ce:label>
                     <sb:reference id="sbref300">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>Government of Malawi</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Health sector resource mapping: FY 2017/18–FY 2019/20</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2018</sb:date>
                              <sb:publisher>
                                 <sb:name>Government of Malawi</sb:name>
                                 <sb:location>Lilongwe</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext300">Government of Malawi. Health sector resource mapping: FY 2017/18–FY 2019/20. Lilongwe: Government of Malawi, 2018.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>31</ce:label>
                     <sb:reference id="sbref310">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O</ce:given-name>
                                 <ce:surname>Sankoh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>KE</ce:given-name>
                                 <ce:surname>Dickson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Faniran</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Births and deaths must be registered in Africa</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet Glob Health</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e33</sb:first-page>
                              <sb:last-page>e34</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext310">Sankoh O, Dickson KE, Faniran S, et al. Births and deaths must be registered in Africa. Lancet Glob Health 2020; 8: e33–34.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>32</ce:label>
                     <sb:reference id="sbref320">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H</ce:given-name>
                                 <ce:surname>Barroy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Sparkes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E</ce:given-name>
                                 <ce:surname>Dale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Mathonnat</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Can low-and-middle income countries increase domestic fiscal space for health: a mixed-methods approach to assess possible sources of expansion</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Health Syst Reform</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>214</sb:first-page>
                              <sb:last-page>226</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext320">Barroy H, Sparkes S, Dale E, Mathonnat J. Can low-and-middle income countries increase domestic fiscal space for health: a mixed-methods approach to assess possible sources of expansion. Health Syst Reform 2018; 4: 214–26.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>33</ce:label>
                     <sb:reference id="sbref330">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>WHO Global Coordination Mechanism on the Prevention and Control of Noncommunicable Diseases</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Final report and recommendations from the Working Group on ways and means of encouraging member states and non-state actors to realize the commitment included in paragraph 45(d) of the Political Declaration of the High-level Meeting of the UN General Assembly on the Prevention and Control of Noncommunicable Diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2015</sb:date>
                              <sb:publisher>
                                 <sb:name>World Health Organization</sb:name>
                                 <sb:location>Geneva</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext330">WHO Global Coordination Mechanism on the Prevention and Control of Noncommunicable Diseases. Final report and recommendations from the Working Group on ways and means of encouraging member states and non-state actors to realize the commitment included in paragraph 45(d) of the Political Declaration of the High-level Meeting of the UN General Assembly on the Prevention and Control of Noncommunicable Diseases. Geneva: World Health Organization, 2015.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>34</ce:label>
                     <sb:reference id="sbref340">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R</ce:given-name>
                                 <ce:surname>Oroxom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A</ce:given-name>
                                 <ce:surname>Glassman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L</ce:given-name>
                                 <ce:surname>McDonald</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structuring and funding development impact bonds for health: nine lessons from Cameroon and beyond</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2018</sb:date>
                              <sb:publisher>
                                 <sb:name>Center for Global Development</sb:name>
                                 <sb:location>Washington, DC</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext340">Oroxom R, Glassman A, McDonald L. Structuring and funding development impact bonds for health: nine lessons from Cameroon and beyond. Washington, DC: Center for Global Development, 2018.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>35</ce:label>
                     <sb:reference id="sbref350">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Coady</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I</ce:given-name>
                                 <ce:surname>Parry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L</ce:given-name>
                                 <ce:surname>Sears</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B</ce:given-name>
                                 <ce:surname>Shang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>How large are global fossil fuel subsidies?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>World Dev</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>91</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>11</sb:first-page>
                              <sb:last-page>27</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext350">Coady D, Parry I, Sears L, Shang B. How large are global fossil fuel subsidies? World Dev 2017; 91: 11–27.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>36</ce:label>
                     <sb:reference id="sbref360">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Verguet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>ZD</ce:given-name>
                                 <ce:surname>Olson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>JB</ce:given-name>
                                 <ce:surname>Babigumira</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet Glob Health</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e288</sb:first-page>
                              <sb:last-page>e296</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext360">Verguet S, Olson ZD, Babigumira JB, et al. Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis. Lancet Glob Health 2015; 3: e288–96.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>37</ce:label>
                     <sb:reference id="sbref370">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Jan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>TL</ce:given-name>
                                 <ce:surname>Laba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>BM</ce:given-name>
                                 <ce:surname>Essue</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Action to address the household economic burden of non-communicable diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>391</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2047</sb:first-page>
                              <sb:last-page>2058</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext370">Jan S, Laba TL, Essue BM, et al. Action to address the household economic burden of non-communicable diseases. Lancet 2018; 391: 2047–58.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>38</ce:label>
                     <sb:reference id="sbref380">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W</ce:given-name>
                                 <ce:surname>Van Biesen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V</ce:given-name>
                                 <ce:surname>Jha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>AK</ce:given-name>
                                 <ce:surname>Abu-Alfa</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Considerations on equity in management of end-stage kidney disease in low- and middle-income countries</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Kidney Int Suppl (2011)</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e63</sb:first-page>
                              <sb:last-page>e71</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext380">Van Biesen W, Jha V, Abu-Alfa AK, et al. Considerations on equity in management of end-stage kidney disease in low- and middle-income countries. Kidney Int Suppl (2011) 2020; 10: e63–71.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>39</ce:label>
                     <sb:reference id="sbref390">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R</ce:given-name>
                                 <ce:surname>Ruiz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K</ce:given-name>
                                 <ce:surname>Strasser-Weippl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Touya</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Improving access to high-cost cancer drugs in Latin America: much to be done</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>123</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1313</sb:first-page>
                              <sb:last-page>1323</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext390">Ruiz R, Strasser-Weippl K, Touya D, et al. Improving access to high-cost cancer drugs in Latin America: much to be done. Cancer 2017; 123: 1313–23.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>40</ce:label>
                     <sb:reference id="sbref400">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W</ce:given-name>
                                 <ce:surname>Isaranuwatchai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y</ce:given-name>
                                 <ce:surname>Teerawattananon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>RA</ce:given-name>
                                 <ce:surname>Archer</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Prevention of non-communicable disease: best buys, wasted buys, and contestable buys</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>BMJ</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>368</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>m141</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext400">Isaranuwatchai W, Teerawattananon Y, Archer RA, et al. Prevention of non-communicable disease: best buys, wasted buys, and contestable buys. BMJ 2020; 368: m141.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>41</ce:label>
                     <sb:reference id="sbref410">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>GT</ce:given-name>
                                 <ce:surname>Eregata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A</ce:given-name>
                                 <ce:surname>Hailu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>ZA</ce:given-name>
                                 <ce:surname>Geletu</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Revision of the Ethiopian essential health service package: an explication of the process and methods used</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Health Syst Reform</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:article-number>e1829313</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext410">Eregata GT, Hailu A, Geletu ZA, et al. Revision of the Ethiopian essential health service package: an explication of the process and methods used. Health Syst Reform 2020; 6: e1829313.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>42</ce:label>
                     <sb:reference id="sbref420">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>GA</ce:given-name>
                                 <ce:surname>Roth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Abate</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>KH</ce:given-name>
                                 <ce:surname>Abate</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>392</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1736</sb:first-page>
                              <sb:last-page>1788</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext420">Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1736–88.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>43</ce:label>
                     <sb:reference id="sbref430">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>Ethiopian Public Health Institute</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ethiopia STEPs report on risk factors for non-communicable diseases and prevalence of selected NCDs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2016</sb:date>
                              <sb:publisher>
                                 <sb:name>Ethiopian Public Health Institute</sb:name>
                                 <sb:location>Addis Ababa</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext430">Ethiopian Public Health Institute. Ethiopia STEPs report on risk factors for non-communicable diseases and prevalence of selected NCDs. Addis Ababa: Ethiopian Public Health Institute, 2016.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>44</ce:label>
                     <sb:reference id="sbref440">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>Ethiopian Public Health Institute</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ethiopia services availability and readiness assessment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2016</sb:date>
                              <sb:publisher>
                                 <sb:name>Ethiopian Public Health Institute</sb:name>
                                 <sb:location>Addis Ababa</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext440">Ethiopian Public Health Institute. Ethiopia services availability and readiness assessment. Addis Ababa: Ethiopian Public Health Institute, 2016.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>45</ce:label>
                     <sb:reference id="sbref450">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>Federal Ministry of Health</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ethiopia health accounts 2016/17</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2019</sb:date>
                              <sb:publisher>
                                 <sb:name>Federal Ministry of Health</sb:name>
                                 <sb:location>Addis Ababa</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext450">Federal Ministry of Health. Ethiopia health accounts 2016/17. Addis Ababa: Federal Ministry of Health, 2019.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>46</ce:label>
                     <sb:reference id="sbref460">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>MT</ce:given-name>
                                 <ce:surname>Tolla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>OF</ce:given-name>
                                 <ce:surname>Norheim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Verguet</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Out-of-pocket expenditures for prevention and treatment of cardiovascular disease in general and specialised cardiac hospitals in Addis Ababa, Ethiopia: a cross-sectional cohort study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>BMJ Glob Health</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:article-number>e000280</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext460">Tolla MT, Norheim OF, Verguet S, et al. Out-of-pocket expenditures for prevention and treatment of cardiovascular disease in general and specialised cardiac hospitals in Addis Ababa, Ethiopia: a cross-sectional cohort study. BMJ Glob Health 2017; 2: e000280.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>47</ce:label>
                     <sb:reference id="sbref470">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>Ministry of Health of Ethiopia</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Essential health services package of Ethiopia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2019</sb:date>
                              <sb:publisher>
                                 <sb:name>Ministry of Health of Ethiopia</sb:name>
                                 <sb:location>Addis Ababa</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext470">Ministry of Health of Ethiopia. Essential health services package of Ethiopia. Addis Ababa: Ministry of Health of Ethiopia, 2019.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>48</ce:label>
                     <sb:reference id="sbref480">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K</ce:given-name>
                                 <ce:surname>Jailobaeva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Falconer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G</ce:given-name>
                                 <ce:surname>Loffreda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Arakelyan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Witter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A</ce:given-name>
                                 <ce:surname>Ager</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An analysis of policy and funding priorities of global actors regarding noncommunicable disease in low- and middle-income countries</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Global Health</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>68</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext480">Jailobaeva K, Falconer J, Loffreda G, Arakelyan S, Witter S, Ager A. An analysis of policy and funding priorities of global actors regarding noncommunicable disease in low- and middle-income countries. Global Health 2021; 17: 68.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>49</ce:label>
                     <sb:reference id="sbref490">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>UN Interagency Task Force on NCDs</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Catalytic fund for non-communicable diseases and mental health</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="interrefs50" xlink:href="https://www.who.int/ncds/un-task-force/catalytic-flyer.pdf" xlink:type="simple">https://www.who.int/ncds/un-task-force/catalytic-flyer.pdf</ce:inter-ref>
                              <sb:date>2020</sb:date>
                              <sb:date-accessed day="19" month="7" year="2021"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext490">UN Interagency Task Force on NCDs. Catalytic fund for non-communicable diseases and mental health 2020. https://www.who.int/ncds/un-task-force/catalytic-flyer.pdf (accessed July 19 2021).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>50</ce:label>
                     <sb:reference id="sbref500">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>TE</ce:given-name>
                                 <ce:surname>Collins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R</ce:given-name>
                                 <ce:surname>Nugent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Webb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E</ce:given-name>
                                 <ce:surname>Placella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T</ce:given-name>
                                 <ce:surname>Evans</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A</ce:given-name>
                                 <ce:surname>Akinnawo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Time to align: development cooperation for the prevention and control of non-communicable diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>BMJ</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>366</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:article-number>l4499</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext500">Collins TE, Nugent R, Webb D, Placella E, Evans T, Akinnawo A. Time to align: development cooperation for the prevention and control of non-communicable diseases. BMJ 2019; 366: l4499.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>51</ce:label>
                     <sb:reference id="sbref510">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R</ce:given-name>
                                 <ce:surname>Nugent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>RV</ce:given-name>
                                 <ce:surname>Barnabas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I</ce:given-name>
                                 <ce:surname>Golovaty</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Costs and cost-effectiveness of HIV/noncommunicable disease integration in Africa: from theory to practice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>AIDS</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>suppl 1</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>S83</sb:first-page>
                              <sb:last-page>S92</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext510">Nugent R, Barnabas RV, Golovaty I, et al. Costs and cost-effectiveness of HIV/noncommunicable disease integration in Africa: from theory to practice. AIDS 2018; 32 (suppl 1): S83–92.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>52</ce:label>
                     <sb:reference id="sbref520">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>Norwegian Ministry of Foreign Affairs</sb:collaboration>
                              <sb:collaboration>Norwegian Ministry of Health and Care Services</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Better health, better lives: combating non-communicable diseases in the context of Norwegian development policy 2020–24</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2019</sb:date>
                              <sb:publisher>
                                 <sb:name>Government of Norway</sb:name>
                                 <sb:location>Oslo</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext520">Norwegian Ministry of Foreign Affairs, Norwegian Ministry of Health and Care Services. Better health, better lives: combating non-communicable diseases in the context of Norwegian development policy 2020–24. Oslo: Government of Norway, 2019.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>53</ce:label>
                     <sb:reference id="sbref530">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>HHP</ce:given-name>
                                 <ce:surname>Kluge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K</ce:given-name>
                                 <ce:surname>Wickramasinghe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>HL</ce:given-name>
                                 <ce:surname>Rippin</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Prevention and control of non-communicable diseases in the COVID-19 response</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>395</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1678</sb:first-page>
                              <sb:last-page>1680</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext530">Kluge HHP, Wickramasinghe K, Rippin HL, et al. Prevention and control of non-communicable diseases in the COVID-19 response. Lancet 2020; 395: 1678–80.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>54</ce:label>
                     <sb:reference id="sbref540">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Kostova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Richter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G</ce:given-name>
                                 <ce:surname>Van Vliet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Mahar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>RL</ce:given-name>
                                 <ce:surname>Moolenaar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of noncommunicable diseases in the pursuit of global health security</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Health Secur</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>288</sb:first-page>
                              <sb:last-page>301</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext540">Kostova D, Richter P, Van Vliet G, Mahar M, Moolenaar RL. The role of noncommunicable diseases in the pursuit of global health security. Health Secur 2021; 19: 288–301.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib55">
                     <ce:label>55</ce:label>
                     <sb:reference id="sbref550">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Bertram</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N</ce:given-name>
                                 <ce:surname>Banatvala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A</ce:given-name>
                                 <ce:surname>Kulikov</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Using economic evidence to support policy decisions to fund interventions for non-communicable diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>BMJ</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>365</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:article-number>l1648</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext550">Bertram M, Banatvala N, Kulikov A, et al. Using economic evidence to support policy decisions to fund interventions for non-communicable diseases. BMJ 2019; 365: l1648.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib56">
                     <ce:label>56</ce:label>
                     <sb:reference id="sbref560">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>MY</ce:given-name>
                                 <ce:surname>Bertram</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K</ce:given-name>
                                 <ce:surname>Sweeny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>JA</ce:given-name>
                                 <ce:surname>Lauer</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Investing in non-communicable diseases: an estimation of the return on investment for prevention and treatment services</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>391</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2071</sb:first-page>
                              <sb:last-page>2078</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext560">Bertram MY, Sweeny K, Lauer JA, et al. Investing in non-communicable diseases: an estimation of the return on investment for prevention and treatment services. Lancet 2018; 391: 2071–78.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib57">
                     <ce:label>57</ce:label>
                     <sb:reference id="sbref570">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Horton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H</ce:given-name>
                                 <ce:surname>Gelband</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Jamison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C</ce:given-name>
                                 <ce:surname>Levin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R</ce:given-name>
                                 <ce:surname>Nugent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Watkins</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ranking 93 health interventions for low- and middle-income countries by cost-effectiveness</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:article-number>e0182951</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext570">Horton S, Gelband H, Jamison D, Levin C, Nugent R, Watkins D. Ranking 93 health interventions for low- and middle-income countries by cost-effectiveness. PLoS One 2017; 12: e0182951.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib58">
                     <ce:label>58</ce:label>
                     <sb:reference id="sbref580">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>KJ</ce:given-name>
                                 <ce:surname>Foreman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N</ce:given-name>
                                 <ce:surname>Marquez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A</ce:given-name>
                                 <ce:surname>Dolgert</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>392</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2052</sb:first-page>
                              <sb:last-page>2090</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext580">Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet 2018; 392: 2052–90.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib59">
                     <ce:label>59</ce:label>
                     <sb:reference id="sbref590">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>LN</ce:given-name>
                                 <ce:surname>Allen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>BD</ce:given-name>
                                 <ce:surname>Nicholson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>BYT</ce:given-name>
                                 <ce:surname>Yeung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F</ce:given-name>
                                 <ce:surname>Goiana-da-Silva</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Implementation of non-communicable disease policies: a geopolitical analysis of 151 countries</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet Glob Health</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e50</sb:first-page>
                              <sb:last-page>e58</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext590">Allen LN, Nicholson BD, Yeung BYT, Goiana-da-Silva F. Implementation of non-communicable disease policies: a geopolitical analysis of 151 countries. Lancet Glob Health 2020; 8: e50–58.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib60">
                     <ce:label>60</ce:label>
                     <sb:reference id="sbref600">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>WHO</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Intersectoral action on health: a path for policy-makers to implement effective and sustainable intersectoral action on health</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2011</sb:date>
                              <sb:publisher>
                                 <sb:name>WHO Centre for Health Development, World Health Organization</sb:name>
                                 <sb:location>Kobe</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext600">WHO. Intersectoral action on health: a path for policy-makers to implement effective and sustainable intersectoral action on health. Kobe: WHO Centre for Health Development, World Health Organization, 2011.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib61">
                     <ce:label>61</ce:label>
                     <sb:reference id="sbref610">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Delobelle</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Big tobacco, alcohol, and food and NCDs in LMICs: an inconvenient truth and call to action comment on “addressing NCDs: challenges from industry market promotion and interferences”</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int J Health Policy Manag</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>727</sb:first-page>
                              <sb:last-page>731</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext610">Delobelle P. Big tobacco, alcohol, and food and NCDs in LMICs: an inconvenient truth and call to action comment on “addressing NCDs: challenges from industry market promotion and interferences”. Int J Health Policy Manag 2019; 8: 727–31.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib62">
                     <ce:label>62</ce:label>
                     <sb:reference id="sbref620">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>WHO</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>WHO report on the global tobacco epidemic, 2017: monitoring tobacco use and prevention policies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2017</sb:date>
                              <sb:publisher>
                                 <sb:name>World Health Organization</sb:name>
                                 <sb:location>Geneva</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext620">WHO. WHO report on the global tobacco epidemic, 2017: monitoring tobacco use and prevention policies. Geneva: World Health Organization, 2017.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib63">
                     <ce:label>63</ce:label>
                     <sb:reference id="sbref630">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C</ce:given-name>
                                 <ce:surname>Lane</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Measuring the effectiveness of health taxes: the cigarette tax scorecard</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="interrefs60" xlink:href="https://www.cgdev.org/blog/measuring-effectiveness-health-taxes-cigarette-tax-scorecard" xlink:type="simple">https://www.cgdev.org/blog/measuring-effectiveness-health-taxes-cigarette-tax-scorecard</ce:inter-ref>
                              <sb:date>Dec, 14 2020</sb:date>
                              <sb:date-accessed day="1" month="9" year="2021"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext630">Lane C. Measuring the effectiveness of health taxes: the cigarette tax scorecard. Dec, 14 2020. https://www.cgdev.org/blog/measuring-effectiveness-health-taxes-cigarette-tax-scorecard (accessed Sept 1, 2021).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib64">
                     <ce:label>64</ce:label>
                     <sb:reference id="sbref640">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Curti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C</ce:given-name>
                                 <ce:surname>Shang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>FJ</ce:given-name>
                                 <ce:surname>Chaloupka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>GT</ce:given-name>
                                 <ce:surname>Fong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tobacco taxation, illegal cigarette supply and geography: findings from the ITC Uruguay Surveys</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Tob Control</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>suppl 1</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>s53</sb:first-page>
                              <sb:last-page>s60</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext640">Curti D, Shang C, Chaloupka FJ, Fong GT. Tobacco taxation, illegal cigarette supply and geography: findings from the ITC Uruguay Surveys. Tob Control 2019; 28 (suppl 1): s53–60.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib65">
                     <ce:label>65</ce:label>
                     <sb:reference id="sbref650">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Watkins</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Policy options for tackling diet-related noncommunicable diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bull World Health Organ</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>97</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>442</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext650">Watkins D. Policy options for tackling diet-related noncommunicable diseases. Bull World Health Organ 2019; 97: 442.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib66">
                     <ce:label>66</ce:label>
                     <sb:reference id="sbref660">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>NCD Risk Factor Collaboration</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>398</sb:volume-nr>
                              </sb:series>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>957</sb:first-page>
                              <sb:last-page>980</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext660">NCD Risk Factor Collaboration. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021; 398: 957–80.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib67">
                     <ce:label>67</ce:label>
                     <sb:reference id="sbref670">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>CG</ce:given-name>
                                 <ce:surname>Kemp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>BJ</ce:given-name>
                                 <ce:surname>Weiner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>KH</ce:given-name>
                                 <ce:surname>Sherr</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Implementation science for integration of HIV and non-communicable disease services in sub-Saharan Africa: a systematic review</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>AIDS</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>suppl 1</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>S93</sb:first-page>
                              <sb:last-page>105</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext670">Kemp CG, Weiner BJ, Sherr KH, et al. Implementation science for integration of HIV and non-communicable disease services in sub-Saharan Africa: a systematic review. AIDS 2018; 32 (suppl 1): S93–105.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib68">
                     <ce:label>68</ce:label>
                     <sb:reference id="sbref680">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>WHO</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A guide to implementation research in the prevention and control of noncommunicable diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2016</sb:date>
                              <sb:publisher>
                                 <sb:name>World Health Organization</sb:name>
                                 <sb:location>Geneva</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext680">WHO. A guide to implementation research in the prevention and control of noncommunicable diseases. Geneva: World Health Organization, 2016.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib69">
                     <ce:label>69</ce:label>
                     <sb:reference id="sbref690">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>MA</ce:given-name>
                                 <ce:surname>Hoffer-Hawlik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>AE</ce:given-name>
                                 <ce:surname>Moran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Burka</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Leveraging telemedicine for chronic disease management in low- and middle-income countries during COVID-19</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Glob Heart</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>63</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext690">Hoffer-Hawlik MA, Moran AE, Burka D, et al. Leveraging telemedicine for chronic disease management in low- and middle-income countries during COVID-19. Glob Heart 2020; 15: 63.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib70">
                     <ce:label>70</ce:label>
                     <sb:reference id="sbref700">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Gospodarowicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Trypuc</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A</ce:given-name>
                                 <ce:surname>D'Cruz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Khader</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Omar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F</ce:given-name>
                                 <ce:surname>Knaul</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cancer services and the comprehensive cancer center</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:edited-book>
                              <sb:editors>
                                 <sb:editor>
                                    <ce:given-name>H</ce:given-name>
                                    <ce:surname>Gelband</ce:surname>
                                 </sb:editor>
                                 <sb:editor>
                                    <ce:given-name>P</ce:given-name>
                                    <ce:surname>Jha</ce:surname>
                                 </sb:editor>
                                 <sb:editor>
                                    <ce:given-name>R</ce:given-name>
                                    <ce:surname>Sankaranarayanan</ce:surname>
                                 </sb:editor>
                                 <sb:editor>
                                    <ce:given-name>S</ce:given-name>
                                    <ce:surname>Horton</ce:surname>
                                 </sb:editor>
                              </sb:editors>
                              <sb:title>
                                 <sb:maintitle>Cancer: disease control priorities</sb:maintitle>
                              </sb:title>
                              <sb:edition>3rd edn.</sb:edition>
                              <sb:book-series>
                                 <sb:series>
                                    <sb:volume-nr>vol 3</sb:volume-nr>
                                 </sb:series>
                              </sb:book-series>
                              <sb:date>2015</sb:date>
                              <sb:publisher>
                                 <sb:name>The International Bank for Reconstruction and Development and The World Bank</sb:name>
                                 <sb:location>Washington, DC</sb:location>
                              </sb:publisher>
                           </sb:edited-book>
                           <sb:pages>
                              <sb:first-page>195</sb:first-page>
                              <sb:last-page>210</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext700">Gospodarowicz M, Trypuc J, D'Cruz A, Khader J, Omar S, Knaul F. Cancer services and the comprehensive cancer center. In: Gelband H, Jha P, Sankaranarayanan R, Horton S, eds. Cancer: disease control priorities, vol 3, 3rd edn. Washington, DC: The International Bank for Reconstruction and Development and The World Bank, 2015: 195–210.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib71">
                     <ce:label>71</ce:label>
                     <sb:reference id="sbref710">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Hensher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Price</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Adomakoh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Referral hospitals</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:edited-book>
                              <sb:editors>
                                 <sb:editor>
                                    <ce:given-name>DT</ce:given-name>
                                    <ce:surname>Jamison</ce:surname>
                                 </sb:editor>
                                 <sb:editor>
                                    <ce:given-name>JG</ce:given-name>
                                    <ce:surname>Breman</ce:surname>
                                 </sb:editor>
                                 <sb:editor>
                                    <ce:given-name>AR</ce:given-name>
                                    <ce:surname>Measham</ce:surname>
                                 </sb:editor>
                                 <sb:et-al/>
                              </sb:editors>
                              <sb:title>
                                 <sb:maintitle>Disease control priorities in developing countries</sb:maintitle>
                              </sb:title>
                              <sb:edition>2nd edn.</sb:edition>
                              <sb:date>2006</sb:date>
                              <sb:publisher>
                                 <sb:name>The International Bank for Reconstruction and Development and The World Bank</sb:name>
                                 <sb:location>Washington, DC</sb:location>
                              </sb:publisher>
                           </sb:edited-book>
                           <sb:pages>
                              <sb:first-page>1229</sb:first-page>
                              <sb:last-page>1243</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext710">Hensher M, Price M, Adomakoh S. Referral hospitals. In: Jamison DT, Breman JG, Measham AR, et al, eds. Disease control priorities in developing countries, 2nd edn. Washington, DC; The International Bank for Reconstruction and Development and The World Bank, 2006: 1229–43.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib72">
                     <ce:label>72</ce:label>
                     <sb:reference id="sbref720">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>WHO</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Making fair choices on the path to universal health coverage: final report of the WHO Consultative Group on Equity and Universal Health Coverage</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2014</sb:date>
                              <sb:publisher>
                                 <sb:name>World Health Organization</sb:name>
                                 <sb:location>Geneva</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext720">WHO. Making fair choices on the path to universal health coverage: final report of the WHO Consultative Group on Equity and Universal Health Coverage. Geneva: World Health Organization, 2014.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib73">
                     <ce:label>73</ce:label>
                     <sb:reference id="sbref730">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Ebrahim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Ordunez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Lloyd-Sherlock</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>McKee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R</ce:given-name>
                                 <ce:surname>Martinez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Soliz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Improving the indicator for premature deaths from noncommunicable diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bull World Health Organ</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>98</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>438</sb:first-page>
                              <sb:last-page>440</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext730">Ebrahim S, Ordunez P, Lloyd-Sherlock P, McKee M, Martinez R, Soliz P. Improving the indicator for premature deaths from noncommunicable diseases. Bull World Health Organ 2020; 98: 438–40.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib74">
                     <ce:label>74</ce:label>
                     <sb:reference id="sbref740">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R</ce:given-name>
                                 <ce:surname>Nugent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>MY</ce:given-name>
                                 <ce:surname>Bertram</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Jan</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Investing in non-communicable disease prevention and management to advance the Sustainable Development Goals</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>391</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2029</sb:first-page>
                              <sb:last-page>2035</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext740">Nugent R, Bertram MY, Jan S, et al. Investing in non-communicable disease prevention and management to advance the Sustainable Development Goals. Lancet 2018; 391: 2029–35.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originalText></full-text-retrieval-response>